Health Insurance (Pathology Services Table) Regulation 2013

Link to law: https://www.comlaw.gov.au/Details/F2013L01978

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now
 
Health Insurance (Pathology Services Table) Regulation 2013
 
Select Legislative Instrument No. 249, 2013
I, Quentin Bryce AC CVO, Governor‑General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, make the following regulation under the Health Insurance Act 1973.
Dated 21 November 2013
Quentin Bryce
Governor‑General
By Her Excellency’s Command
Peter Dutton
Minister for Health
 
 
  
  
  
Contents
1............ Name of regulation.............................................................................. 1
2............ Commencement................................................................................... 1
3............ Authority............................................................................................. 1
4............ Schedule(s)......................................................................................... 1
5............ Pathology services table...................................................................... 1
6............ Dictionary........................................................................................... 1
Schedule 1—Pathology services table                                                       2
Part 1—Preliminary                                                                                                             2
Division 1.1—Interpretation                                                                                     2
1.1.1...... Abbreviations...................................................................................... 2
Division 1.2—General application provisions                                                 3
1.2.1...... Precedence of items............................................................................. 3
1.2.2...... Circumstances in which services rendered following 2 requests to be taken to have been rendered following one request............................................................................................................ 3
1.2.3...... Services to which clause 1.2.2 does not apply.................................... 4
1.2.4...... Referral of designated tests by one pathology practitioner to another.. 5
1.2.5...... Items not to be split............................................................................. 7
1.2.6...... Certain pathology services to be treated as one service....................... 7
1.2.7...... Meaning of set of pathology services.................................................. 8
1.2.8...... Satisfying requirements described in pathology service.................... 10
Part 2—Services and fees                                                                                                11
Division 2.1—Group P1: haematology                                                             11
2.1.1...... Services to which clause 1.2.2 does not apply.................................. 11
2.1.2...... Item taken to refer only to the first service of a particular kind.......... 11
Division 2.2—Group P2: chemical                                                                      19
2.2.1...... Creatinine ratios................................................................................ 19
2.2.2...... Services to which clause 1.2.2 does not apply.................................. 19
2.2.3...... Limitation on certain items................................................................ 19
2.2.4...... Serum B12 and red cell folate testing................................................ 20
2.2.5...... Thyroid function testing.................................................................... 20
2.2.6...... Limitation on certain items................................................................ 21
2.2.7...... Nutritional and toxicity metals testing............................................... 21
Division 2.3—Group P3: microbiology                                                             35
2.3.1...... Meaning of serial examinations or cultures..................................... 35
2.3.2...... Antigen detection.............................................................................. 35
2.3.3...... Investigation for hepatitis serology................................................... 35
2.3.4...... Limitation on certain items................................................................ 36
2.3.5...... Hepatitis C viral RNA testing........................................................... 36
Division 2.4—Group P4: immunology                                                               47
2.4.1...... Limitation on certain items................................................................ 47
2.4.2...... Tests in Group P4 relating to antibodies........................................... 47
2.4.3...... HLA‑B27 typing............................................................................... 47
2.4.4...... Antineutrophil cytoplasmic antibody tests......................................... 47
Division 2.5—Group P5: tissue pathology                                                      55
2.5.1...... Tests on biopsy material.................................................................... 55
Division 2.6—Group P6: cytology                                                                       60
2.6.1...... Tests on biopsy material.................................................................... 60
Division 2.7—Group P7: genetics                                                                        64
2.7.1...... Haemochromatosis testing................................................................ 64
2.7.2...... HLA‑B27 typing............................................................................... 64
Division 2.8—Group P8: infertility and pregnancy tests                        70
2.8.1...... Limitation on item 73523.................................................................. 70
Division 2.9—Group P9: simple basic pathology tests                             71
Division 2.10—Group P10: patient episode initiation                               72
2.10.1.... Items in Group P10 not to apply in certain circumstances................. 72
Division 2.11—Group P11: specimen referred                                             78
2.11.1.... Items in Group P11 not to apply in certain circumstances................. 78
2.11.2.... Application of an item in Group P11 to a service excludes certain other items         78
2.11.3.... Circumstances in which an item in Group P11 does not apply......... 78
Division 2.12—Group P12: management of bulk‑billed services        80
2.12.1.... Application of items 74990 and 74991............................................. 80
Division 2.13—Group P13: bulk billing incentive for episodes consisting of a P10 service        84
Part 3—Abbreviations                                                                                                      86
Part 4—Complexity levels for histopathology items                                     120
Part 5—Dictionary                                                                                                            127
Schedule 2—Repeals                                                                                                        132
Health Insurance (Pathology Services Table) Regulation 2012                    132
 
 
 
1  Name of regulation
                   This regulation is the Health Insurance (Pathology Services Table) Regulation 2013.
2  Commencement
                   This regulation commences on the day after it is registered.
3  Authority
                   This regulation is made under the Health Insurance Act 1973.
4  Schedule(s)
                   Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
5  Pathology services table
                   For subsection 4A(1) of the Act, this regulation prescribes a table of pathology services set out in Schedule 1.
6  Dictionary
                   The Dictionary in Part 5 of Schedule 1 defines certain words and expressions that are used in this regulation, and includes references to certain words and expressions that are defined elsewhere in this regulation.
Schedule 1—Pathology services table
Note:       See section 5.
Part 1—Preliminary
Division 1.1—Interpretation
1.1.1  Abbreviations
             (1)  The abbreviations in Part 3 may be used to identify particular pathology services or groups of pathology services.
             (2)  The names of services or drugs not listed in Part 3 must be written in full.
Division 1.2—General application provisions
1.2.1  Precedence of items
             (1)  If a service is described:
                     (a)  in an item in general terms; and
                     (b)  in another item in specific terms;
only the item that describes the service in specific terms applies to the service.
             (2)  Subject to subclause (3), if:
                     (a)  subclause (1) does not apply; and
                     (b)  a service is described in 2 or more items;
only the item that provides the lower or lowest fee for the service applies to the service.
             (3)  If an item is expressed to include a pathology service that is described in another item, the other item does not apply to the service in addition to the first‑mentioned item, whether or not the services described in the 2 items are requested separately.
1.2.2  Circumstances in which services rendered following 2 requests to be taken to have been rendered following one request
             (1)  In subclause (2):
service includes assay, estimation and test.
             (2)  Two or more pathology services (other than services to which, under clause 1.2.3, 2.1.1 or 2.2.2, this clause does not apply) rendered for a patient following 2 or more requests are taken to have been rendered following a single request if:
                     (a)  the services are listed in the same item; and
                     (b)  that item is not item 74990 or 74991; and
                     (c)  the patient’s need for the services was determined under subsection 16A(1) of the Act on the same day even if the services are rendered by an approved pathology practitioner on more than 1 day.
1.2.3  Services to which clause 1.2.2 does not apply
             (1)  Clause 1.2.2 does not apply to a pathology service described in subclause (2) if:
                     (a)  under a request for a service, other than a request for a service described in paragraph (2)(a), no more than 6 tests are requested; and
                     (b)  the tests are performed within 6 months of the request; and
                     (c)  the pathology provider of the service writes on the account for the service that the service has a rule 3 exemption.
             (2)  For subclause (1), the pathology services are:
                     (a)  estimation of prothrombin time (INR) for a patient undergoing anticoagulant therapy; and
                     (b)  quantitative estimation of lithium for a patient undergoing lithium therapy; and
                     (c)  a service described in item 65070 in relation to a patient undergoing chemotherapy for neoplastic disease or immunosuppressant therapy; and
                     (d)  a service described in item 65070 in relation to
clozaril, ticlopidine hydrochloride, methotrexate, gold, sulphasalazine or penicillamine therapy of a patient; and
                     (e)  a service described in any of items 66500 to 66512, in relation to methotrexate or leflunomide therapy of a patient; and
                      (f)  quantitative estimation of urea, creatinine and electrolytes in relation to:
                              (i)  cis‑platinum or cyclosporin therapy of a patient; or
                             (ii)  chronic renal failure of a patient being treated
in a dialysis program conducted by a recognised hospital; and
                     (g)  quantitative estimation of albumin and calcium in relation to therapy of a patient with vitamin D, its metabolites or analogues; and
                     (h)  quantitative estimation of calcium, phosphate, magnesium, urea, creatinine and electrolytes for a cancer patient receiving bisphosphonate infusions.
1.2.4  Referral of designated tests by one pathology practitioner to another
             (1)  In this clause:
designated test means a pathology test relating to a patient episode that is a test of a kind mentioned in item 65150, 65175, 66650, 66695, 66711, 66722, 66785, 66800, 66812, 66819, 66825, 69384, 69494, 71089, 71153 or 77165.
             (2)  This clause applies if one or more designated tests are referred by a referring APP to a receiving APP in another approved pathology authority.
             (3)  If a referring APP has rendered one or more designated tests:
                     (a)  the amount mentioned in item 65150, 65153, 65175, 65176, 65177, 65178, 66650, 66695, 66698, 66701, 66704, 66707, 66711, 66722, 66725, 66728, 66731, 66785, 66800, 66803, 66812, 66819, 66825, 69384, 69387, 69390, 69393, 69396, 69494, 69495, 71089, 71091, 71153, 71155, 71157, 77165, 71166 or 71167 (as the case may be) is payable for each designated test rendered by the referring APP; and
                     (b)  subject to subclause (5), the amount mentioned in item 65158, 65181, 66652, 66697, 66715, 66724, 66790, 66805, 66817, 66821, 66827, 69401, 69498, 71092, 71156 or 71170 (as the case may be) is payable for each designated test rendered by the receiving APP.
             (4)  If a referring APP has not rendered a designated test:
                     (a)  for the first designated test that is rendered by the receiving APP—the amount mentioned in item 65157, 65180, 66651, 66696, 66714, 66723, 66789, 66804, 66816, 66820, 66826, 69400, 69497, 71090, 71154 or 71169 (as the case may be) is payable; and
                     (b)  for each subsequent designated test (if any) that is rendered by the receiving APP—subject to subclause (6), the amount mentioned in item 65158, 65181, 66652, 66697, 66715, 66724, 66790, 66805, 66817, 66821, 66827, 69401, 69498, 71092, 71156 or 71170 (as the case may be) is payable for each test rendered.
             (5)  For paragraph (3)(b), the maximum number of designated tests for which the fee mentioned in the relevant item is payable is as follows:
                     (a)  for item 66652, 66715, 66790, 66817, 66821 or 66827:
                           
                     (b)  for item 65158, 66805, 69498 or 71092:
                           
                     (c)  for item 71156 or 71170:
                           
                     (d)  for item 65181 or 66724:
                           
where:
X is the number of designated tests rendered by a referring APP.
             (6)  For paragraph (4)(b), the maximum number of designated tests for which the fee mentioned in the relevant item is payable is as follows:
                     (a)  for item 66652, 66715, 66790, 66817, 66821 or 66827—1;
                     (b)  for item 65158, 66805, 69498 or 71092—2;
                     (c)  for item 71156 or 71170—3;
                     (d)  for item 65181 or 66724—4.
             (7)  Items in Group P10 (Patient episode initiation) do not apply to a receiving APP in subclause (2).
1.2.5  Items not to be split
                   Except as stated in clause 1.2.4 the amount mentioned in an item is payable only to one approved pathology practitioner for a single patient episode.
1.2.6  Certain pathology services to be treated as one service
             (1)  In this clause:
general practitioner means a medical practitioner who:
                     (a)  is not a consultant physician in any specialty; and
                     (b)  is not a specialist in any specialty.
set of pathology services has the meaning given by subclause 1.2.7(1).
             (2)  If a general practitioner, participating midwife or participating nurse practitioner requests a set of pathology services, the pathology services in the set are to be treated as individual pathology services in accordance with this clause.
             (3)  If the fee mentioned in an item that describes any of the services in the set of pathology services is higher than the fees mentioned in the other items that describe the services in the set:
                     (a)  the pathology service described in the first‑mentioned item is to be treated as one pathology service; and
                     (b)  either:
                              (i)  the pathology service in the set that is described in the item that mentions the second‑highest fee is to be treated as one pathology service; or
                             (ii)  if 2 or more items that describe any of those services mentions the second‑highest fee—the pathology service described in the item that mentions the second‑highest fee, and has the lowest item number, is to be treated as one pathology service; and
                     (c)  the pathology services in the set, other than the services that are to be treated as one pathology service under paragraphs (a) and (b), are to be treated as one pathology service.
             (4)  If the fees mentioned in 2 or more items that describe any of the services in the set of pathology services are the same, and higher than the fees mentioned in the other items that describe the services in the set:
                     (a)  the pathology service in the set that is described in the item that mentions the highest fee, and has the lowest item number, is to be treated as one pathology service; and
                     (b)  the pathology service in the set that is described in the item that mentions the highest fee, and has the second‑lowest item number, is to be treated as one pathology service; and
                     (c)  the pathology services in the set, other than the services that are to be treated as one pathology service under paragraphs (a) and (b), are to be treated as one pathology service.
             (5)  If pathology services are to be treated as one pathology service under paragraph (3)(c) or (4)(c), the fee for the one pathology service is the highest fee mentioned in any of the items that describe the pathology services that are to be treated as the one pathology service.
1.2.7  Meaning of set of pathology services
             (1)  In clause 1.2.6:
set of pathology services means a group of pathology services:
                     (a)  that consist of services that are described in at least 4 different items; and
                     (b)  all of which are requested in a single patient episode; and
                     (c)  each of which relates to a patient who is not an admitted patient of a hospital; and
                     (d)  none of which is referred to in item 66900, 69484, 73053 or 73055.
             (2)  However, a set of pathology services does not include the following items:
                     (a)  an item in Group P10 (Patient episode initiation), Group P11 (Specimen referred), Group P12 (Management of bulk‑billed services) or Group P13 (Bulk billing incentive for episodes consisting of a P10 service);
                     (b)  if a service is requested by an approved pathology practitioner of an approved pathology authority and rendered by another approved pathology practitioner of an approved pathology authority that is not related to the approved pathology authority of the first‑mentioned approved pathology practitioner—item 65079, 65082, 65157, 65158, 65166, 65180, 65181, 66606, 66609, 66610, 66639, 66642, 66651, 66652, 66663, 66666, 66696, 66697, 66714, 66715, 66723, 66724, 66780, 66783, 66789, 66790, 66792, 66804, 66805, 66816, 66817, 66820, 66821, 66826, 66827, 66832, 69325, 69328, 69331, 69379, 69383, 69400, 69401, 69419, 69451, 69489, 69492, 69497, 69498, 69500, 71076, 71090, 71092, 71096, 71148, 71154, 71156, 71169, 71170, 73309, 73312, 73315, 73318, 73321 or 73324.
             (3)  An approved pathology authority is related to another approved pathology authority for paragraph (2)(b) if:
                     (a)  both approved pathology authorities are employed (including employed under contract) by the same person, whether or not the person is also an approved pathology authority; or
                     (b)  either of the approved pathology authorities is employed (including employed under contract) by the other; or
                     (c)  both approved pathology authorities are corporations and are connected entities within the meaning of the Corporations Act 2001; or
                     (d)  the approved pathology authorities are partners (whether or not either or both of the approved pathology authorities are individuals and whether or not other persons are in partnership with either or both of the approved pathology authorities); or
                     (e)  both approved pathology authorities are operated by the Commonwealth or an authority of the Commonwealth; or
                      (f)  both approved pathology authorities are operated by the same State or internal Territory or an authority of the same State or internal Territory.
1.2.8  Satisfying requirements described in pathology service
                   Unless the contrary intention appears, a requirement contained in the description of a pathology service in Part 2 is satisfied if:
                     (a)  for a requirement for information—the information:
                              (i)  is included in the request for the service; or
                             (ii)  was supplied in writing on an earlier occasion to
the approved pathology authority that rendered
the service, and has been kept by the approved pathology authority; or
                     (b)  for a requirement for laboratory test results—the results are:
                              (i)  included in the request for the service; or
                             (ii)  obtained from another laboratory test performed in the same patient episode; or
                            (iii)  included in results from an earlier laboratory test that have been kept by the approved pathology authority.
Part 2—Services and fees
Division 2.1—Group P1: haematology
2.1.1  Services to which clause 1.2.2 does not apply
             (1)  Clause 1.2.2 does not apply to a pathology service described in item 65060, 65070, 65120, 65123, 65126, 65129, 65150, 65153 or 65156 if:
                     (a)  the service is rendered in relation to one or more specimens taken on any of not more than 6 occasions in a period of 24 hours; and
                     (b)  the service is rendered to an inpatient of a hospital; and
                     (c)  the service is rendered in relation to each specimen as soon as possible after the specimen is taken; and
                     (d)  the pathology provider of the service writes on the account for the service that the service has a rule 3 exemption.
             (2)  Clause 1.2.2 does not apply to a pathology service described in item 65109 or 65110 if:
                     (a)  the service is rendered:
                              (i)  for a service described in item 65109—on one of not more than 5 occasions in a period of 24 hours; and
                             (ii)  for a service described in item 65110—on one of not more than 2 occasions in a period of 24 hours; and
                     (b)  the service was requested on a separate occasion to any other occasions on which the service was requested in the period of 24 hours; and
                     (c)  the pathology provider of the service writes on the account for the service that the service has a rule 3 exemption.
2.1.2  Item taken to refer only to the first service of a particular kind
             (1)  For an item in Group P1 (Haematology):
                     (a)  if pathology services of a kind mentioned in item 65090 or 65093 are rendered for a patient during a period when the patient is in hospital, the item applies only to the first pathology service of that kind rendered for the patient during the period; and
                     (b)  if:
                              (i)  tests (except tests mentioned in item 65099, 65102, 65105 or 65108) are carried out in relation to a patient episode; and
                             (ii)  specimen material from the patient episode is stored; and
                            (iii)  in response to a request made within 14 days of the patient episode, further tests (except tests mentioned in item 65099, 65102, 65105 or 65108) are carried out on the stored material;
                            the later tests and the earlier tests are taken to be part of one patient episode.
             (2)  Items 65102 and 65108 apply only if a minimum of 6 units are issued for a patient’s care in any 1 day.
             (3)  For items 65099 and 65102:
compatibility tests by crossmatch means that, in addition to all the tests mentioned in paragraphs (a) and (b) of the item, donor red cells from each unit must have been tested directly against the serum of the patient by one or more accepted crossmatching techniques.
 
Group P1—Haematology

Item
Pathology service
Fee ($)

65060
Haemoglobin, erythrocyte sedimentation rate, blood viscosity—one or more tests
7.85

65066
Examination of:
(a) a blood film by special stains to demonstrate Heinz bodies, parasites or iron; or
(b) a blood film by enzyme cytochemistry for neutrophil alkaline phosphatase, alpha‑naphthyl acetate esterase or chloroacetate esterase; or
(c) a blood film using any other special staining methods including periodic acid Schiff and Sudan Black; or
(d) a urinary sediment for haemosiderin;
including a service described in item 65072
10.40

65070
Erythrocyte count, haematocrit, haemoglobin, calculation or measurement of red cell index or indices, platelet count, leucocyte count and manual or instrument generated differential count (not being a service where haemoglobin only is requested)—one or more instrument‑generated set of results from a single sample and (if performed):
(a) a morphological assessment of a blood film; and
(b) any service in item 65060 or 65072
16.95

65072
Examination for reticulocytes including a reticulocyte count by any method—one or more tests
10.20

65075
Haemolysis or metabolic enzymes—assessment by one or more of the following tests:
(a) erythrocyte autohaemolysis test;
(b) erythrocyte osmotic fragility test;
(c) sugar water test;
(d) G–6–PD (qualitative or quantitative) test;
(e) pyruvate kinase (qualitative or quantitative) test;
(f) acid haemolysis test;
(g) quantitation of muramidase in serum or urine;
(h) Donath Landsteiner antibody test;
(i) other erythrocyte metabolic enzyme tests
51.95

65078
Tests for the diagnosis of thalassaemia consisting of haemoglobin electrophoresis or chromatography and at least 2 of:
(a) examination for HbH; or
(b) quantitation of HbA2; or
(c) quantitation of HbF;
including (if performed) any service described in item 65060 or 65070
90.20

65079
A test described in item 65078 if rendered by a receiving APP—one or more tests
90.20

65081
Tests for the investigation of haemoglobinopathy consisting of haemoglobin electrophoresis or chromatography and at least one of:
(a) heat denaturation test; or
(b) isopropanol precipitation test; or
(c) tests for the presence of haemoglobin S; or
(d) quantitation of any haemoglobin fraction (including S, C, D, E);
including (if performed) any service described in item 65060, 65070 or 65078
96.60

65082
A test described in item 65081 if rendered by a receiving APP—one or more tests
96.60

65084
Bone marrow trephine biopsy—histopathological examination of sections of bone marrow and examination of aspirated material (including clot sections where necessary), including (if performed) any test described in item 65060, 65066 or 65070
165.85

65087
Bone marrow—examination of aspirated material (including clot sections where necessary), including (if performed) any test described in item 65060, 65066 or 65070
83.10

65090
Blood grouping (including back‑grouping if performed)—ABO and Rh (D antigen)
11.15

65093
Blood grouping—Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system—one or more systems, including item 65090 (if performed)
22.00

65096
Blood grouping (including back‑grouping if performed), and examination of serum for Rh and other blood group antibodies, including:
(a) identification and quantitation of any antibodies detected; and
(b) (if performed) any test described in item 65060 or 65070
41.00

65099
Compatibility tests by crossmatch—all tests performed on any 1 day for up to 6 units, including:
(a) all grouping checks of the patient and donor; and
(b) examination for antibodies and, if necessary, identification of any antibodies detected; and
(c) (if performed) any tests described in item 65060, 65070, 65090 or 65096
108.90

65102
Compatibility tests by crossmatch—all tests performed on any 1 day in excess of 6 units, including:
(a) all grouping checks of the patient and donor; and
(b) examination for antibodies and, if necessary, identification of any antibodies detected; and
(c) (if performed) any tests described in item 65060, 65070, 65090, 65096, 65099 or 65105
164.60

65105
Compatibility testing using at least a 3 cell panel and issue of red cells for transfusion—all tests performed on any 1 day for up to 6 units, including:
(a) all grouping checks of the patient and donor; and
(b) examination for antibodies and, if necessary, identification of any antibodies detected; and
(c) (if performed) any tests described in item 65060, 65070, 65090 or 65096
108.90

65108
Compatibility testing using at least a 3 cell panel and issue of red cells for transfusion—all tests performed on any 1 day in excess of 6 units, including:
(a) all grouping checks of the patient and donor; and
(b) examination for antibodies and, if necessary, identification of any antibodies detected; and
(c) (if performed) any tests described in item 65060, 65070, 65090, 65096, 65099 or 65105
164.60

65109
Release of fresh frozen plasma or cryoprecipitate for the use in a patient for the correction of a coagulopathy—one release
12.90

65110
Release of compatible fresh platelets for the use in a patient for platelet support as prophylaxis to minimise bleeding or during active bleeding—one release
12.90

65111
Examination of serum for blood group antibodies (including identification and, if necessary, quantitation of any antibodies detected)
23.20

65114
One or more of the following tests:
(a) direct Coombs (antiglobulin) test;
(b) qualitative or quantitative test for cold agglutinins or heterophil antibodies
9.10

65117
One or more of the following tests:
(a) spectroscopic examination of blood for chemically altered haemoglobins;
(b) detection of methaemalbumin (Schumm’s test)
20.25

65120
Prothrombin time (including INR where appropriate), activated partial thromboplastin time, thrombin time (including test for the presence of heparin), test for factor XIII deficiency (qualitative), Echis test, Stypven test, reptilase time, fibrinogen, or one of fibrinogen degradation products, fibrin monomer or D‑dimer—one test
13.70

65123
Two tests described in item 65120
20.35

65126
Three tests described in item 65120
27.85

65129
Four or more tests described in item 65120
35.50

65137
A test for the presence of lupus anticoagulant, not being a service connected with a service to which item 65175, 65176, 65177, 65178 or 65179 applies
25.35

65142
Confirmation or clarification of an abnormal or indeterminate result of a test mentioned in item 65175, by testing a specimen collected on a different day—one or more tests
25.35

65144
Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or other substances, or heparin, low molecular weight heparins, heparinoid or other drugs—one or more tests
56.55

65147
Quantitation of anti‑Xa activity when monitoring is required for a patient receiving a low molecular weight heparin or heparinoid—one test
37.90

65150
Quantitation of von Willebrand factor antigen, von Willebrand factor activity (ristocetin cofactor assay), von Willebrand factor collagen binding activity, factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, Fletcher factor, Fitzgerald factor, circulating coagulation factor inhibitors other than by Bethesda assay—one test
70.90

65153
Two tests described in item 65150
141.85

65156
Three or more tests described in item 65150
212.75

65157
A test described in item 65150, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP—one test
70.90

65158
A test described in item 65150, if rendered by a receiving APP, where one or more tests in the item have been rendered by the referring APP—one test
70.90

65159
Quantitation of circulating coagulation factor inhibitors by Bethesda assay—one test
70.90

65162
Examination of a maternal blood film for the presence of fetal red blood cells (Kleihauer test)
10.45

65165
Detection and quantitation of fetal red blood cells in the maternal circulation by detection of red cell antigens using flow cytometric methods including (if performed) any test described in item 65070 or 65162
34.45

65166
A test described in item 65165 if rendered by a receiving APP—one or more tests
34.45

65171
A test for the presence of antithrombin III deficiency, protein C deficiency, protein S deficiency or activated protein C resistance in a first degree relative of a person who has a proven deficiency mentioned in this item—one or more tests
25.35

65175
A test for the presence of antithrombin III deficiency, protein C deficiency, protein S deficiency, lupus anticoagulant, activated protein C resistance, if the request for the test specifically identifies that the patient has a history of venous thromboembolism—quantitation by one or more techniques—one test
25.35

65176
Two tests described in item 65175
48.65

65177
Three tests described in item 65175
71.95

65178
Four tests described in item 65175
95.20

65179
Five tests described in item 65175
118.50

65180
A test described in item 65175, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP—one test
25.35

65181
A test described in item 65175, if rendered by a receiving APP, where one or more tests in the item have been rendered by the referring APP—one test
23.30


Division 2.2—Group P2: chemical
2.2.1  Creatinine ratios
                   A pathology service mentioned in an item in Group P2 (Chemical) (except item 66500) that:
                     (a)  involves the measurement of a substance in urine; and
                     (b)  requires calculation of a substance/creatinine ratio;
is taken to include the measurement of creatinine necessary for the calculation.
2.2.2  Services to which clause 1.2.2 does not apply
                   Clause 1.2.2 does not apply to a pathology service described in item 66500, 66503, 66506, 66509, 66512, 66584 or 66800 if:
                     (a)  the service is rendered in relation to one or more specimens taken on any of not more than 6 occasions in a period of 24 hours; and
                     (b)  the service is rendered to an inpatient of a hospital; and
                     (c)  the service is rendered in relation to each specimen as soon as possible after the specimen is taken; and
                     (d)  the pathology provider of the service writes on the account for the service that the service has a rule 3 exemption.
2.2.3  Limitation on certain items
             (1)  For any particular patient, the following items are applicable not more than twice in a 12 month period:
                     (a)  items 66539 and 66607;
                     (b)  item 66605, 66606 or 66610.
             (2)  For any particular patient, each of items 66551 and 66660 is applicable not more than 4 times in a 12 month period.
             (3)  For any particular patient, each of items 66554 and 66830 is applicable not more than 6 times in a 12 month period.
             (4)  For any particular patient, item 66626 is applicable not more than 36 times in a 12 month period.
             (5)  For any particular patient, item 66750 or 66751 is applicable not more than once in a pregnancy.
             (6)  For any particular patient, item 66517 is applicable not more than 3 times in a pregnancy.
2.2.4  Serum B12 and red cell folate testing
             (1)  Items 66599 and 66602 do not apply to more than 3 patient episodes that include a service mentioned in item 66599 or 66602, or any combination of those items, in a 12 month period.
             (2)  Item 66599 does not apply to a service mentioned in that item if the service was provided as part of the same patient episode as a service mentioned in item 66602.
2.2.5  Thyroid function testing
             (1)  For item 66719:
abnormal level of TSH means a level of TSH that is outside the normal reference range for the particular method of assay used to determine the level.
             (2)  Unless paragraph (a) of item 66719 is satisfied, the amount mentioned in the item is not payable for a pathology service mentioned in the item unless the pathologist who renders the service has a written statement from the medical practitioner who requested the service that satisfies subclause (3).
             (3)  The written statement from the medical practitioner must indicate:
                     (a)  that the tests are required for a particular purpose, being a purpose mentioned in paragraph (b) of item 66719; or
                     (b)  that the medical practitioner who requested the tests suspects the patient has pituitary dysfunction; or
                     (c)  that the patient is on drugs that interfere with thyroid hormone metabolism or function.
2.2.6  Limitation on certain items
             (1)  For any particular patient, each of items 66655 and 66659 is applicable not more than once in a 12 month period.
             (2)  For any particular patient, each of items 66819, 66820, 66821, 66822, 66825, 66826, 66827 and 66828 is applicable not more than 3 times in a 6 month period.
2.2.7  Nutritional and toxicity metals testing
             (1)  In this clause:
metal toxicity testing group means items 66825, 66826, 66827, 66828, 66831 and 66832.
nutritional metals testing group means items 66819, 66820, 66821 and 66822.
             (2)  An item in the nutritional metals testing group or the metal toxicity testing group does not apply to a service performed if medicare benefits are paid or payable for tests that are performed for the same patient in 3 patient episodes requested within 6 months before the request for that service, under any of:
                     (a)  that item; or
                     (b)  the other item in the same group; or
                     (c)  an item in the other group.
 
Group P2—Chemical

Item
Pathology service
Fee ($)

66500
Quantitation in serum, plasma, urine or other body fluid (except amniotic fluid), by any method, except reagent tablet or reagent strip, (with or without reflectance meter) of acid phosphatase, alanine aminotransferase, albumin, alkaline phosphatase, ammonia, amylase, aspartate aminotransferase, bicarbonate, bilirubin (total), bilirubin (any fractions), C‑reactive protein, calcium (total or corrected for albumin), chloride, creatine kinase, creatinine, gamma glutamyl transferase, globulin, glucose, lactate dehydrogenase, lipase, magnesium, phosphate, potassium, sodium, total cholesterol, total protein, triglycerides, urate or urea—one test
9.70

66503
Two tests described in item 66500
11.65

66506
Three tests described in item 66500
13.65

66509
Four tests described in item 66500
15.65

66512
Five or more tests described in item 66500
17.70

66517
Quantitation of bile acids in blood in pregnancy
19.65

66518
Investigation of cardiac or skeletal muscle damage by quantitative measurement of creatine kinase isoenzymes, troponin or myoglobin in blood—tests performed on only one specimen in a 24 hour period
20.05

66519
Investigation of cardiac or skeletal muscle damage by quantitative measurement of creatine kinase isoenzymes, troponin or myoglobin in blood—tests performed on 2 or more specimens in a 24 hour period
40.15

66536
Quantitation of HDL cholesterol
11.05

66539
Electrophoresis of serum for demonstration of lipoprotein subclasses:
(a) if the cholesterol is >6.5 mmol/L and triglyceride >4.0 mmol/L; or
(b) in the diagnosis of types III and IV hyperlipidaemia
30.60

66542
Oral glucose tolerance test for the diagnosis of diabetes mellitus, that includes:
(a) administration of glucose; and
(b) at least 2 measurements of blood glucose; and
(c) (if performed) any test described in item 66695
18.95

66545
Oral glucose challenge test in pregnancy for the detection of gestational diabetes that includes:
(a) administration of glucose; and
(b) one or 2 measurements of blood glucose; and
(c) (if performed) any test in item 66695
15.80

66548
Oral glucose tolerance test in pregnancy for the diagnosis of gestational diabetes that includes:
(a) administration of glucose; and
(b) at least 3 measurements of blood glucose; and
(c) (if performed) any test in item 66695
19.90

66551
Quantitation of glycosylated haemoglobin performed in the management of established diabetes
16.80

66554
Quantitation of glycosylated haemoglobin performed in the management of pre‑existing diabetes where the patient is pregnant—including a service in item 66551 (if performed)
16.80

66557
Quantitation of fructosamine performed in the management of established diabetes—each test to a maximum of 4 tests in a 12 month period
9.70

66560
Microalbumin—quantitation in urine
20.10

66563
Osmolality, estimation by osmometer, in serum or in urine—one or more tests
24.70

66566
Quantitation of:
(a) blood gases (including pO2, oxygen saturation and pCO2); and
(b) bicarbonate and pH;
including any other measurement (e.g. haemoglobin, lactate, potassium or ionised calcium) or calculation performed on the same specimen—one or more tests on one specimen
33.70

66569
Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 2 specimens performed on any 1 day
42.60

66572
Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 3 specimens performed on any 1 day
51.55

66575
Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 4 specimens performed on any 1 day
60.45

66578
Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 5 specimens performed on any 1 day
69.35

66581
Quantitation of blood gases, bicarbonate and pH as described in item 66566 on 6 or more specimens performed on any 1 day
78.25

66584
Quantitation of ionised calcium (except if performed as part of item 66566)—one test
9.70

66587
Urine acidification test for the diagnosis of renal tubular acidosis including the administration of an acid load, and pH measurements on 4 or more urine specimens and at least one blood specimen
47.55

66590
Calculus, analysis of one or more
30.60

66593
Ferritin—quantitation, except if requested as part of iron studies
18.00

66596
Iron studies, consisting of quantitation of:
(a) serum iron; and
(b) transferrin or iron binding capacity; and
(c) ferritin
32.55

66599
Serum B12 or red cell folate and, if required, serum folate
23.60

66602
Serum B12 and red cell folate and, if required, serum folate
42.95

66605
Vitamins—quantitation of vitamin B1, B2, B3, B6 or C in blood, urine or other body fluid—one or more tests
30.60

66606
A test described in item 66605 if rendered by a receiving APP—one or more tests
30.60

66607
Vitamins—quantitation of vitamin A or E in blood, urine or other body fluid—one or more tests in a 6 month period
75.75

66608
Vitamin D or D fractions—one or more tests
39.05

66609
A test described in item 66608 if rendered by a receiving APP—one or more tests
39.05

66610
A test described in item 66607 if rendered by a receiving APP—one or more tests
75.75

66623
All qualitative and quantitative tests on blood, urine or other body fluid for:
(a) a drug or drugs of abuse (including illegal drugs and legally available drugs taken other than in appropriate dosage); or
(b) ingested or absorbed toxic chemicals;
including a service described in item 66800, 66803, 66806, 66812 or 66815 (if performed), but excluding:
(c) the surveillance of sports people and athletes for performance improving substances; and
(d) the monitoring of patients participating in a drug abuse treatment program
41.50

66626
Detection or quantitation or both of a drug, or drugs, of abuse or a therapeutic drug, on a sample collected from a patient participating in a drug abuse treatment program, including all tests on blood, urine or other body fluid, not including:
(a) the surveillance of sports people and athletes for performance improving substances; and
(b) the detection of nicotine and metabolites in smoking withdrawal programs
24.10

66629
Beta‑2‑microglobulin—quantitation in serum, urine or other body fluids—one or more tests
20.10

66632
Caeruloplasmin, haptoglobins, or prealbumin—quantitation in serum, urine or other body fluids—one or more tests
20.10

66635
Alpha‑1‑antitrypsin—quantitation in serum, urine or other body fluid—one or more tests
20.10

66638
Isoelectric focusing or similar methods for determination of alpha‑1‑antitrypsin phenotype in serum—one or more tests
49.05

66639
A test described in item 66638 if rendered by a receiving APP—one or more tests
29.20

66641
Electrophoresis of serum or other body fluid to demonstrate:
(a) the isoenzymes of lactate dehydrogenase; or
(b) the isoenzymes of alkaline phosphatase;
including the preliminary quantitation of total relevant enzyme activity—one or more tests
29.20

66642
A test described in item 66641 if rendered by a receiving APP—one or more tests
29.20

66644
C‑1 esterase inhibitor—quantitation
20.15

66647
C‑1 esterase inhibitor—functional assay
45.10

66650
Alpha‑fetoprotein, CA‑15.3 antigen (CA15.3), CA‑19.9 antigen (CA19.9), CA‑125 antigen (C125), cancer associated serum antigen (CASA), carcinoembryonic antigen (CEA), human chorionic gonadotrophin (HCG), neuron specific enolase (NSE) thyroglobulin in serum or other body fluid, in the monitoring of malignancy or in the detection or monitoring of gestational trophoblastic disease or a hepatic or germ cell tumour—quantitation—one test
24.35

66651
A test described in item 66650, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP—one test
24.35

66652
A test described in item 66650, if rendered by a receiving APP, where one or more tests in the item have been rendered by the referring APP—one test
20.30

66653
Two or more tests described in item 66650
44.60

66655
Prostate specific antigen—quantitation
20.15

66656
Prostate specific antigen (PSA) quantitation in the monitoring of previously diagnosed prostatic disease (including a test to which item 66655 applies)
20.15

66659
Prostate specific antigen (PSA), quantitation of 2 or more fractions of PSA and any derived index, including, if performed, a test described in item 66656, in the follow up of a PSA result that lies at or above the age‑related median but below the age‑related, method‑specific 97.5% reference limit
37.30

66660
Prostate specific antigen (PSA), quantitation of 2 or more fractions of PSA and any derived index, including, if performed, a test described in item 66656, in the follow up of a PSA result that lies at or above the age‑related, method‑specific 97.5% reference limit, but below 10 µg/L
37.30

66662
Quantitation of hormone receptors on proven primary breast or ovarian carcinoma or a metastasis from a breast or ovarian carcinoma or a subsequent lesion in the breast—one or more tests
79.95

66663
A test described in item 66662 if rendered by a receiving APP—one or more tests
79.95

66665
Lead quantitation in blood or urine (other than for occupational health screening purposes) to a maximum of 3 tests in a 6 month period—each test
30.60

66666
A test described in item 66665 if rendered by a receiving APP—one or more tests
30.60

66667
Quantitation of serum zinc in a patient receiving intravenous alimentation—each test
30.60

66671
Quantitation of serum aluminium in a patient in a renal dialysis program—each test
36.90

66674
Quantitation of:
(a) faecal fat; or
(b) breath hydrogen in response to loading with disaccharides;
one or more tests within a 28 day period
39.95

66677
Test for tryptic activity in faeces in the investigation of diarrhoea of longer than 4 weeks duration in children under 6 years
11.15

66680
Quantitation of disaccharidases and other enzymes in intestinal tissue—one or more tests
74.45

66683
Enzymes—quantitation in solid tissue or tissues other than blood elements or intestinal tissue—one or more tests
74.45

66686
Performance of one or more of the following procedures:
(a) growth hormone suppression by glucose loading;
(b) growth hormone stimulation by exercise;
(c) dexamethasone suppression test;
(d) sweat collection by iontophoresis for chloride analysis;
(e) pharmacological stimulation of growth hormone
50.65

66695
Quantitation in blood or urine of hormones and hormone binding proteins—ACTH, aldosterone, androstenedione, C‑peptide, calcitonin, cortisol, DHEAS, 11‑deoxycortisol, dihydrotestosterone, FSH, gastrin, glucagon, growth hormone, hydroxyprogesterone, insulin, LH, oestradiol, oestrone, progesterone, prolactin, PTH, renin, sex hormone binding globulin, somatomedin C(IGF –1), free or total testosterone, urine steroid fraction or fractions, vasoactive intestinal peptide—one test
30.50

66696
A test described in item 66695, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP
30.50

66697
A test described in item 66695, if rendered by a receiving APP, where one or more tests in the item have been rendered by the referring APP—each test to a maximum of 4 tests
13.20

66698
Two tests described in item 66695
43.70

66701
Three tests described in item 66695
56.90

66704
Four tests described in item 66695
70.15

66707
Five or more tests described in item 66695
83.35

66711
Quantitation in saliva of cortisol in:
(a) the investigation of Cushing’s syndrome; or
(b) the management of children with congenital adrenal hyperplasia;
one test
30.15

66712
Two tests described in item 66711
43.05

66714
A test described in item 66711, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP
30.15

66715
A test described in item 66711, if rendered by a receiving APP, where one test in the item has been rendered by the referring APP—one test
12.85

66716
TSH quantitation
25.05

66719
Thyroid function tests (comprising the service described in item 66716 and one or more of the following tests—free thyroxine, free T3, for a patient, if at least one of the following conditions is satisfied:
(a) the patient has an abnormal level of TSH;
(b) the tests are performed:
(i) for the purpose of monitoring thyroid disease in the patient; or
(ii) to investigate the sick euthyroid syndrome if the patient is an admitted patient; or
(iii) to investigate dementia or psychiatric illness of the patient; or
(iv) to investigate amenorrhoea or infertility of the patient;
(c) the medical practitioner who requested the tests suspects the patient has a pituitary dysfunction;
(d) the patient is on drugs that interfere with thyroid hormone metabolism or function
34.80

66722
TSH quantitation described in item 66716 and one test described in item 66695
37.90

66723
A test described in item 66722, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP—one test
37.90

66724
A test described in item 66722, if rendered by a receiving APP, where one or more tests in the item have been rendered by the referring APP—one test
13.15

66725
TSH quantitation described in item 66716 and 2 tests described in item 66695
51.05

66728
TSH quantitation described in item 66716 and 3 tests described in item 66695
64.20

66731
TSH quantitation described in item 66716 and 4 tests described in item 66695
77.40

66734
TSH quantitation described in item 66716 and 5 tests described in item 66695
90.55

66743
Quantitation of alpha‑fetoprotein in serum or other body fluids during pregnancy except if requested as part of item 66750 or 66751
20.10

66749
Amniotic fluid, spectrophotometric examination of, and quantitation of:
(a) lecithin/sphingomyelin ratio; or
(b) palmitic acid, phosphatidylglycerol or lamellar body phospholipid; or
(c) bilirubin, including correction for haemoglobin;
one or more tests
32.95

66750
Quantitation, in pregnancy, of any 2 of the following to detect foetal abnormality:
(a) total human chorionic gonadotrophin (total HCG);
(b) free alpha human chorionic gonadotrophin (free alpha HCG);
(c) free beta human chorionic gonadotrophin (free beta HCG);
(d) pregnancy associated plasma protein A (PAPP‑A);
(e) unconjugated oestriol (uE3);
(f) alpha‑fetoprotein (AFP);
including (if performed) a service described in item 73527 or 73529
39.75

66751
Quantitation, in pregnancy, of any 3 or more tests described in item 66750
55.25

66752
Quantitation of acetoacetate, beta‑hydroxybutyrate, citrate, oxalate, total free fatty acids, cysteine, homocysteine, cystine, lactate, pyruvate or other amino acids and hydroxyproline (except if performed as part of item 66773 or 66776)—one test
24.70

66755
Two or more tests described in item 66752
38.85

66756
Quantitation of 10 or more amino acids for the diagnosis of inborn errors of metabolism—up to 4 tests in a 12 month period on specimens of plasma, CSF and urine
98.30

66757
Quantitation of 10 or more amino acids for monitoring of previously diagnosed inborn errors of metabolism in one tissue type
98.30

66758
Quantitation of angiotensin converting enzyme, or cholinesterase—one or more tests
24.70

66761
Test for reducing substances in faeces by any method (except reagent strip or dipstick)
13.15

66764
Examination for faecal occult blood (including tests for haemoglobin and its derivatives in the faeces except by reagent strip or dip stick methods) with a maximum of 3 examinations on specimens collected on separate days in a 28 day period
8.90

66767
Two examinations described in item 66764 performed on separately collected and identified specimens
17.85

66770
Three examinations described in item 66764 performed on separately collected and identified specimens
26.70

66773
Quantitation of products of collagen breakdown or formation for the monitoring of patients with proven low bone mineral density and, if performed, a service described in item 66752—one or more tests
24.65

66776
Quantitation of products of collagen breakdown or formation for the monitoring of patients with metabolic bone disease or Paget’s disease of bone and, if performed, a service described in item 66752—one or more tests
24.65

66779
Adrenaline, noradrenaline, dopamine, histamine, hydroxyindoleacetic acid (5HIAA), hydroxymethoxymandelic acid (HMMA), homovanillic acid (HVA), metanephrines, methoxyhydroxyphenylethylene glycol (MHPG), phenylacetic acid (PAA) or serotonin—quantitation—one or more tests
39.95

66780
A test described in item 66779 if rendered by a receiving APP—one or more tests
39.95

66782
Porphyrins or porphyrins precursors—detection in plasma, red cells, urine or faeces—one or more tests
13.15

66783
A test described in item 66782 if rendered by a receiving APP—one or more tests
13.15

66785
Porphyrins or porphyrins precursors—quantitation in plasma, red cells, urine or faeces—one test
39.95

66788
Porphyrins or porphyrins precursors—quantitation in plasma, red cells, urine or faeces—2 or more tests
65.85

66789
A test described in item 66785 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP—one test
39.95

66790
A test described in item 66785, if rendered by a receiving APP, where one or more tests in the item have been rendered by the referring APP—one test
25.90

66791
Porphyrin biosynthetic enzymes—measurement of activity in blood cells or other tissues—one or more tests
74.45

66792
A test described in item 66791 if rendered by a receiving APP—one or more tests
74.45

66800
Quantitation in blood, urine or other body fluid by any method (except reagent tablet or reagent strip) of any of the following used therapeutically by the patient from whom the specimen was taken: amikacin, carbamazepine, digoxin, disopyramide, ethanol, ethosuximide, gentamicin, lignocaine, lithium, netilmicin, paracetamol, phenobarbitone, phenytoin, primidone, procainamide, quinidine, salicylate, theophylline, tobramycin, valproate or vancomycin—one test
18.15

66803
Two tests described in item 66800
30.50

66804
A test described in item 66800 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP—one test
18.15

66805
A test described in item 66800, if rendered by a receiving APP, where one or more tests in the item have been rendered by the referring APP—one test
12.35

66806
Three tests described in item 66800
41.85

66812
Quantitation, not elsewhere described in this table by any method or methods, in blood, urine or other body fluid, of a drug being used therapeutically by the patient from whom the specimen was taken—one test
34.80

66815
Two tests described in item 66812
59.55

66816
A test described in item 66812 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP—one test
34.80

66817
A test described in item 66812, if rendered by a receiving APP, where one or more tests in the item have been rendered by the referring APP—one test
24.75

66819
Quantitation of copper, manganese, selenium or zinc (except if item 66667 applies), in blood, urine or other body fluid—one test
30.60

66820
A test described in item 66819 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP—one test
30.60

66821
A test described in item 66819, if rendered by a receiving APP, where one or more tests in the item have been rendered by the referring APP—one test
21.80

66822
Quantitation of copper, manganese, selenium or zinc (except if item 66667 applies), in blood, urine or other body fluid—2 or more tests
52.45

66825
Quantitation of aluminium (except if item 66671 applies), arsenic, beryllium, cadmium, chromium, gold, mercury, nickel or strontium, in blood, urine or other body fluid or tissue—one test
30.60

66826
A test described in item 66825 if rendered by a receiving APP where no tests have been rendered by the referring APP—one test
30.60

66827
A test described in item 66825, if rendered by a receiving APP, where one or more tests in the item have been rendered by the referring APP—one test
21.80

66828
Quantitation of aluminium (except if item 66671 applies), arsenic, beryllium, cadmium, chromium, gold, mercury, nickel or strontium, in blood, urine or other body fluid or tissue—2 or more tests
52.45

66830
Quantitation of BNP or NT‑proBNP for the diagnosis of heart failure in patients presenting with dyspnoea in a hospital emergency department
58.50

66831
Quantitation of copper or iron in liver tissue biopsy
30.95

66832
A test described in item 66831 if rendered by a receiving APP
30.95

66900
Carbon‑labelled urea breath test using oral C‑13 or C‑14 urea, including the measurement of exhaled 13CO2 or 14CO2, (except if item 12533 of the general medical services table applies) for:
(a) the confirmation of Helicobactor pylori colonisation; or
(b) the monitoring of the success of eradication of Helicobactor pylori
77.65

Division 2.3—Group P3: microbiology
2.3.1  Meaning of serial examinations or cultures
serial examinations or cultures, for an item in Group P3 (Microbiology), means:
                     (a)  a series of examinations or cultures requested on one occasion whether or not:
                              (i)  the materials are received on different days by the approved pathology practitioner; or
                             (ii)  the examinations or cultures were requested on one or more request forms by the treating practitioner; and
                     (b)  if:
                              (i)  tests are carried out in relation to a patient episode; and
                             (ii)  specimen material from the patient episode is stored; and
                            (iii)  in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;
                            the later tests and the earlier tests are taken to be part of one patient episode.
2.3.2  Antigen detection
                   If a pathology service described in item 69316, 69317, 69319, 69494, 69495, 69496, 69497 or 69498 is rendered as a pathologist‑determinable service, the amount mentioned in the item is not payable for the service unless the recognised pathologist who renders the service records, in writing, the reasons for rendering the service.
2.3.3  Investigation for hepatitis serology
                   The fee applying in a single patient episode that includes any of items 69475, 69478 and 69481 is the fee specified for only one of those items.
2.3.4  Limitation on certain items
             (1)  For any particular patient, item 69336 is applicable not more than once in each period of 7 days.
             (2)  For any particular patient, the following items are applicable not more than once in a 12 month period:
                     (a)  item 69482;
                     (b)  item 69491 or 69492;
                     (c)  item 69499 or 69500.
             (3)  For any particular patient, item 69418 or 69419 is applicable not more than twice in a 24 month period.
             (4)  For any particular patient, item 69380, 69488 or 69489 is applicable not more than twice in a 12 month period.
             (5)  For any particular patient, each of items 69445, 69451 and 69483 is applicable not more than 4 times in a 12 month period.
2.3.5  Hepatitis C viral RNA testing
                   For items 69499 and 69500:
Hepatitis C sero‑positive, for a patient, means 2 different assays of Hepatitis C antibodies are positive.
serological status is uncertain, for a patient, means any result where 2 different assays of Hepatitis C antibodies are inconclusive.
 
Group P3—Microbiology

Item
Pathology service
Fee ($)

69300
Microscopy of wet film material other than blood, from one or more sites, obtained directly from a patient (not cultures) including (if performed):
(a) differential cell count; or
(b) examination for dermatophytes; or
(c) dark ground illumination; or
(d) stained preparation or preparations using any relevant stain or stains;
one or more tests
12.50

69303
Culture and (if performed) microscopy to detect pathogenic micro‑organisms from nasal swabs, throat swabs, eye swabs and ear swabs (except swabs taken for epidemiological surveillance), including (if performed):
(a) pathogen identification and antibiotic susceptibility testing; or
(b) a service described in item 69300;
specimens from one or more sites
22.00

69306
Microscopy and culture to detect pathogenic micro‑organisms from skin or other superficial sites, including (if performed):
(a) pathogen identification and antibiotic susceptibility testing; or
(b) a service described in items 69300, 69303, 69312 and 69318;
one or more tests on one or more specimens
33.75

69309
Microscopy and culture to detect dermatophytes and other fungi causing cutaneous disease, from skin scrapings, skin biopsies, hair and nails (excluding swab specimens) and including (if performed):
(a) the detection of antigens not elsewhere specified in this table; or
(b) a service described in items 69300, 69303, 69306, 69312 and 69318;
one or more tests on one or more specimens
48.15

69312
Microscopy and culture to detect pathogenic micro‑organisms from urethra, vagina, cervix or rectum (except for faecal pathogens), including (if performed):
(a) pathogen identification and antibiotic susceptibility testing; or
(b) a service described in items 69300, 69303, 69306 and 69318;
one or more tests on one or more specimens
33.75

69316
Detection of Chlamydia trachomatis by any method—one test
28.65

69317
This item applies if:
(a) one test described in item 69316 is performed; and
(b) one test described in item 69494 is performed
35.85

69318
Microscopy and culture to detect pathogenic micro‑organisms from specimens of sputum (except when part of items 69324, 69327 and 69330), including (if performed):
(a) pathogen identification and antibiotic susceptibility testing; or
(b) a service described in items 69300, 69303, 69306 and 69312;
one or more tests on one or more specimens
33.75

69319
This item applies if:
(a) one test described in item 69316 is performed; and
(b) 2 tests described in item 69494 are performed
42.95

69321
Microscopy and culture of post‑operative wounds, aspirates of body cavities, synovial fluid, CSF or operative or biopsy specimens, for the presence of pathogenic micro‑organisms involving aerobic and anaerobic cultures and the use of different culture media, and including (if performed):
(a) pathogen identification and antibiotic susceptibility testing; or
(b) a service described in item 69300, 69303, 69306, 69312 or 69318;
specimens from one or more sites
48.15

69324
Microscopy (with appropriate stains) and culture for mycobacteria—one specimen of sputum, urine or other body fluid or one operative or biopsy specimen, including (if performed):
(a) microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or
(b) pathogen identification and antibiotic susceptibility testing;
including a service mentioned in item 69300
43.00

69325
A service described in item 69324 if the microscopy and culture is performed by a receiving APP
43.00

69327
Microscopy (with appropriate stains) and culture for mycobacteria—2 specimens of sputum, urine or other body fluids or operative or biopsy specimens, including (if performed):
(a) microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or
(b) pathogen identification and antibiotic susceptibility testing;
including a service described in item 69300
85.00

69328
A service described in item 69327 if the microscopy and culture is performed by a receiving APP
85.00

69330
Microscopy (with appropriate stains) and culture for mycobacteria—3 specimens of sputum, urine or other body fluids or operative or biopsy specimens, including (if performed):
(a) microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or
(b) pathogen identification and antibiotic susceptibility testing;
including a service described in item 69300
128.00

69331
A service described in item 69330 if the microscopy and culture is performed by a receiving APP
128.00

69333
Urine examination (including serial examination) by any means other than simple culture by dip slide, including:
(a) cell count; and
(b) culture; and
(c) colony count; and
(d) (if performed) stained preparations; and
(e) (if performed) identification of cultured pathogens; and
(f) (if performed) antibiotic susceptibility testing; and
(g) (if performed) examination for pH, specific gravity, blood, protein, urobilinogen, sugar, acetone or bile salts
20.55

69336
Microscopy of faeces for ova, cysts and parasites, that includes the use of:
(a) a concentration technique; and
(b) fixed stains or antigen detection for cryptosporidia and giardia;
and includes a service mentioned in item 69300 (if performed)
33.45

69339
Microscopy of faeces for ova, cysts and parasites using concentration techniques examined after examination described in item 69336 performed on a separately collected and identified specimen collected within 7 days of the examination described in item 69336—not more than one examination in a 7 day period
19.10

69345
Culture and (if performed) microscopy without concentration techniques of faeces for faecal pathogens, using at least 2 selective or enrichment media and culture in at least 2 different atmospheres including (if performed):
(a) pathogen identification and antibiotic susceptibility testing; and
(b) the detection of clostridial toxins; and
(c) a service described in item 69300;
not more than one examination in a 7 day period
52.90

69354
Blood culture for pathogenic micro‑organisms (other than viruses), including sub‑cultures and (if performed):
(a) identification of any cultured pathogen; and
(b) necessary antibiotic susceptibility testing;
to a maximum of 3 sets of cultures—one set of cultures
30.75

69357
Two sets of cultures described in item 69354
61.45

69360
Three sets of cultures described in item 69354
92.20

69363
Detection of Clostridium difficile or Clostridium difficile toxin (except if a service described in item 69345 has been performed)—one or more tests
28.65

69378
Quantitation of HIV viral RNA load in plasma or serum in the monitoring of a HIV sero‑positive patient not on antiretroviral therapy—one or more tests
180.25

69379
A test described in item 69378 if the quantitation is performed by a receiving APP—one or more tests on one or more specimens
180.25

69380
Genotypic testing for HIV antiretroviral resistance in a patient with confirmed HIV infection if the patient’s viral load is greater than 1 000 copies per ml at any of the following times:
(a) at presentation;
(b) before antiretroviral therapy;
(c) when treatment with combination antiretroviral agents fails;
maximum of 2 tests in a 12 month period
770.30

69381
Quantitation of HIV viral RNA load in plasma or serum in the monitoring of a HIV sero‑positive patient on antiretroviral therapy—one or more tests on one or more specimens
180.25

69382
Quantitation of HIV viral RNA load in cerebrospinal fluid in a HIV sero‑positive patient—one or more tests on one or more specimens
180.25

69383
A test described in item 69381 if the quantitation is performed by a receiving APP—one or more tests on one or more specimens
180.25

69384
Quantitation of one antibody to microbial antigens not elsewhere described in this table—one test
15.65

69387
Two tests described in item 69384
29.00

69390
Three tests described in item 69384
42.35

69393
Four tests described in item 69384
55.70

69396
Five or more tests described in item 69384
69.10

69400
A test described in item 69384 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP—one test
15.65

69401
A test described in item 69384 if a referring APP has performed a test or tests described in item 69384—each test to a maximum of 4 tests
13.35

69405
Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:
(a) the determination of one of the following: rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody, HIV antibody; and
(b) (if performed) a service described in one or more of items 69384, 69475, 69478 and 69481
15.65

69408
Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:
(a) the determination of 2 of the following: rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody, HIV antibody; and
(b) (if performed) a service described in one or more of items 69384, 69475, 69478 and 69481
29.00

69411
Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:
(a) the determination of 3 of the following: rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody, HIV antibody; and
(b) (if performed) a service described in one or more of items 69384, 69475, 69478 and 69481
42.35

69413
Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:
(a) the determination of 4 of the following: rubella immune status, specific syphilis serology, carriage of Hepatitis B, Hepatitis C antibody, HIV antibody; and
(b) (if performed) a service described in one or more of items 69384, 69475, 69478 and 69481
55.70

69415
Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including:
(a) the determination of all of the following: rubella immune status, specific syphilis serology, carriage of hepatitis B, hepatitis C antibody, HIV antibody; and
(b) (if performed) a service described in one or more of items 69384, 69475, 69478 and 69481
69.10

69418
A test for high risk human papillomaviruses (HPV) in a patient who:
(a) within the 2 year period before the test, has received excisional or ablative treatment for high grade squamous intraepithelial lesions (HSIL) of the cervix; or
(b) within the 2 year period before the test, has had a positive HPV test after excisional or ablative treatment for HSIL of the cervix; or
(c) is undergoing annual cytological review following treatment for HSIL of the cervix;
one test
63.55

69419
A test described in item 69418 if the test is performed by a receiving APP—one test
63.55

69445
Detection of hepatitis C viral RNA in a patient undertaking antiviral therapy for chronic HCV hepatitis (including a service described in item 69499)—one test
92.20

69451
A test described in item 69445 if the test is performed by a receiving APP—one test
92.20

69471
Test of cell‑mediated immunity in blood for the detection of latent tuberculosis in an immunosuppressed or immunocompromised patient—one test
34.90

69472
Detection of antibodies to Epstein Barr Virus using specific serology—one test
15.65

69474
Detection of antibodies to Epstein Barr Virus using specific serology—2 or more tests
28.65

69475
Detection of hepatitis antigens or antibodies to determine immune status or viral carriage following exposure or vaccination to Hepatitis A, Hepatitis B, Hepatitis C or Hepatitis D—one test
15.65

69478
Two tests described in item 69475
29.25

69481
Investigation of infectious causes of acute or chronic hepatitis—3 tests described in item 69475
40.55

69482
Quantitation of hepatitis B viral DNA in patients who are hepatitis B surface antigen positive and have chronic hepatitis B but are not receiving antiviral therapy—one test
152.10

69483
Quantitation of hepatitis B viral DNA in patients who:
(a) are hepatitis B surface antigen positive; and
(b) have chronic hepatitis B; and
(c) are receiving antiviral therapy;
one test
152.10

69484
Supplementary test for hepatitis B surface antigen or hepatitis C antibody using a different assay on a specimen that yielded a reactive result on initial testing
17.10

69488
Quantitation of HCV RNA load in plasma or serum in:
(a) the pre‑treatment evaluation, of a patient with chronic HCV hepatitis, for antiviral therapy; or
(b) the assessment of efficacy of antiviral therapy for such a patient;
if the test is requested by, or on the advice of, the specialist or consultant physician who manages the treatment of the patient (including a service described in item 69445 or 69499)
180.25

69489
A test described in item 69488 if the test is performed by a receiving APP
180.25

69491
Nucleic acid amplification and determination of hepatitis C virus (HCV) genotype if:
(a) the patient is HCV RNA positive and is being evaluated for antiviral therapy of chronic HCV hepatitis; and
(b) the request for the test is made by, or on the advice of, the specialist or consultant physician managing the treatment of the patient
204.80

69492
A service described in item 69491 if the test is performed by a receiving APP
204.80

69494
Detection of a virus, microbial antigen or microbial nucleic acid (not elsewhere described in this table)—one test
28.65

69495
Two tests described in item 69494
35.85

69496
Three or more tests described in item 69494
43.05

69497
This item applies to a test described in item 69494 if:
(a) a referring APP has not performed the test described in item 69494; and
(b) a receiving APP performs the test described in item 69494;
one test
28.65

69498
This item applies to a test described in item 69494 if:
(a) a referring APP has performed the test or tests described in item 69494; and
(b) a receiving APP has performed the test or tests described in item 69494;
one test
7.20

69499
Detection of hepatitis C viral RNA if at least one of the following criteria is satisfied:
(a) the patient is hepatitis C sero‑positive;
(b) the patient’s serological status is uncertain after testing;
(c) the test is performed for the purpose of:
(i) determining the hepatitis C status of an immunosuppressed or immunocompromised patient; or
(ii) the detection of acute hepatitis C prior to seroconversion where considered necessary for the clinical management of the patient
92.20

69500
A test described in item 69499 if the test is performed by a receiving APP
92.20

Division 2.4—Group P4: immunology
2.4.1  Limitation on certain items
             (1)  For any particular patient, items 71075, 71127, 71135 and 71137 are applicable not more than twice in a 12 month period.
             (2)  For any particular patient, item 71079 is applicable not more than 4 times in a 12 month period.
             (3)  For any particular patient, item 71077 is applicable not more than 6 times in a 12 month period.
2.4.2  Tests in Group P4 relating to antibodies
                   For items 71119, 71121, 71123 and 71125, if:
                     (a)  tests are carried out in relation to a patient episode; and
                     (b)  specimen material from the patient episode is stored; and
                     (c)  in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;
the later tests and the earlier tests are taken to be part of one patient episode.
2.4.3  HLA‑B27 typing
                   If a pathology service mentioned in item 71148 is rendered as a pathologist‑determinable service, the amount mentioned in the item is not payable for a pathology service mentioned in the item unless the recognised pathologist who renders the service records, in writing, the reasons for rendering the service and the result of the pathology service mentioned in item 71147.
2.4.4  Antineutrophil cytoplasmic antibody tests
                   For subsection 16A(3) of the Act, a request for an antineutrophil cytoplasmic antibody immunofluorescence test is taken to include a request for an antineutrophil proteinase 3 antibody test and an antimyeloperoxidase antibody test if:
                     (a)  the immunofluorescence test performed as a result of the request is abnormal; or
                     (b)  a previous immunofluorescence test was abnormal; or
                     (c)  those antibodies have been previously detected.
 
Group P4—Immunology

Item
Pathology service
Fee ($)

71057
Electrophoresis, quantitative and qualitative, of serum, urine or other body fluid, collected in a 28 day period, to demonstrate:
(a) protein classes; or
(b) presence and amount of paraprotein;
including the preliminary quantitation of total protein, albumin and globulin—one specimen type
32.90

71058
Examination as described in item 71057—2 or more specimen types
50.50

71059
Immunofixation, immunoelectrophoresis or isoelectric focusing of:
(a) urine for detection of Bence Jones proteins; or
(b) serum, plasma, or other body fluid;
and characterisation of a paraprotein or cryoglobulin—examination of one specimen type (e.g. serum, urine or CSF)
35.65

71060
Examination as described in item 71059 of 2 or more specimen types
44.05

71062
Electrophoresis and immunofixation or immunoelectrophoresis or isoelectric focusing of CSF for the detection of oligoclonal bands and including if required electrophoresis of the patient’s serum for comparison purposes—one or more tests
44.05

71064
Detection and quantitation of cryoglobulins or cryofibrinogen—one or more tests
20.75

71066
Quantitation of total immunoglobulin A (by any method) in serum, urine, or other body fluid—one test
14.55

71068
Quantitation of total immunoglobulin G (by any method) in serum, urine, or other body fluid—one test
14.55

71069
Two tests described in item 71066, 71068, 71072 or 71074
22.75

71071
Three or more tests described in item 71066, 71068, 71072 or 71074
30.95

71072
Quantitation of total immunoglobulin M (by any method) in serum, urine, or other body fluid—one test
14.55

71073
Quantitation of all 4 immunoglobulin G subclasses
106.15

71074
Quantitation of total immunoglobulin D (by any method) in serum, urine, or other body fluid—one test
14.55

71075
Quantitation of immunoglobulin E (total)—one test
23.00

71076
A test described in item 71073 if the test is performed by a receiving APP—one test
106.15

71077
Quantitation of immunoglobulin E (total) in the follow up of a patient with proven immunoglobulin‑E‑secreting myeloma, proven congenital immunodeficiency or proven allergic bronchopulmonary aspergillosis—one test
27.05

71079
Detection of specific immunoglobulin E antibodies to single or multiple potential allergens
26.80

71081
Quantitation of total haemolytic complement
40.55

71083
Quantitation of complement components C3 and C4 or properdin factor B—one test
20.15

71085
Two tests described in item 71083
28.95

71087
Three or more tests described in item 71083
37.70

71089
Quantitation of complement components or breakdown products of complement proteins not elsewhere described in an item in this table—one test
29.15

71090
This item applies to a test described in item 71089 if:
(a) a referring APP has not performed the test described in item 71089; and
(b) a receiving APP performs the test described in item 71089;
one test
29.15

71091
Two tests described in item 71089
52.85

71092
This item applies to a test described in item 71089 if:
(a) a referring APP has performed the test or tests described in item 71089; and
(b) a receiving APP performs the test or tests described in item 71089;
one test
23.70

71093
Three or more tests described in item 71089
76.45

71095
Quantitation of serum or plasma eosinophil cationic protein, or both, to a maximum of 3 assays in a 12 month period, for monitoring the response to therapy in corticosteroid treated asthma, in a child aged less than 12 years
40.55

71096
A test described in item 71095 if the quantitation is performed by a receiving APP
40.55

71097
Antinuclear antibodies—detection in serum or other body fluids, including quantitation if required
24.45

71099
Double‑stranded DNA antibodies—quantitation by one or more methods other than the Crithidia method
26.50

71101
Antibodies to one or more extractable nuclear antigens—detection in serum or other body fluids
17.40

71103
Characterisation of an antibody detected in a service described in item 71101 (including that service)
52.05

71106
Rheumatoid factor—detection by any technique in serum or other body fluids, including quantitation if required
11.30

71119
Antibodies to tissue antigens not elsewhere specified in this table—detection of one antibody, including quantitation if required
17.35

71121
Detection of 2 antibodies specified in item 71119
20.80

71123
Detection of 3 antibodies specified in item 71119
24.25

71125
Detection of 4 or more antibodies specified in item 71119
27.65

71127
Functional tests for lymphocytes—quantitation, other than by microscopy, of:
(a) proliferation induced by one or more mitogens; or
(b) proliferation induced by one or more antigens; or
(c) estimation of one or more mixed lymphocyte reactions;
including a test described in item 65066 or 65070 (if performed)
176.35

71129
Two tests described in item 71127
217.85

71131
Three or more tests described in item 71127
259.35

71133
Investigation of recurrent infection, by qualitative assessment, for the presence of defects in oxidative pathways in neutrophils by the nitroblue tetrazolium (NBT) reduction test
10.40

71134
Investigation of recurrent infection, by quantitative assessment, of oxidative pathways by flow cytometric techniques, including a test described in item 71133 (if performed)
104.05

71135
Quantitation of neutrophil function, comprising at least 2 of the following:
(a) chemotaxis;
(b) phagocytosis;
(c) oxidative metabolism;
(d) bactericidal activity;
including any test described in item 65066, 65070, 71133 or 71134 (if performed)
207.95

71137
Quantitation of cell‑mediated immunity by multiple antigen delayed type hypersensitivity intradermal skin testing using a minimum of 7 antigens
30.25

71139
Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations, including a total lymphocyte count or total leucocyte count by any method, on one or more specimens of blood, CSF or serous fluid
104.05

71141
Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations on one or more disaggregated tissue specimens
197.35

71143
Characterisation of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations for the diagnosis (but not monitoring) of an immunological or haematological malignancy, including a service described in one or both of items 71139 and 71141 (if performed), on a specimen of blood, CSF, serous fluid or disaggregated tissue
260.00

71145
Characterisation of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations for the diagnosis (but not monitoring) of an immunological or haematological malignancy, including a service described in one or more of items 71139, 71141 and 71143 (if performed) on 2 or more specimens of disaggregated tissues or one specimen of disaggregated tissue and one or more specimens of blood, CSF or serous fluid
424.50

71146
Enumeration of CD34+ cells, only for the purposes of autologous or directed allogeneic haemopoietic stem cell transplantation, including a total white cell count on the pheresis collection
104.05

71147
HLA‑B27 typing
40.55

71148
A test described in item 71147 if a receiving APP performs the test
40.55

71149
Complete tissue typing for 4 HLA‑A and HLA‑B Class I antigens (including any separation of leucocytes), including (if performed) a service described in item 71147
108.25

71151
Tissue typing for HLA‑DR, HLA‑DP and HLA‑DQ Class II antigens (including any separation of leucocytes)—phenotyping or genotyping of 2 or more antigens
118.85

71153
Testing, for assessment or diagnosis of systemic inflammatory disease or vasculitis, for the presence of an antibody by one of the following tests:
(a) antineutrophil cytoplasmic antibody (ANCA) immunofluorescence test;
(b) antineutrophil proteinase 3 antibody (PR3 ANCA) test;
(c) antimyeloperoxidase antibody (MPO ANCA) test;
(d) antiglomerular basement membrane antibody (GBM ANCA) test
34.55

71154
This item applies to a test described in item 71153 if:
(a) a referring APP has performed a test or tests described in item 71153; and
(b) a receiving APP performs the test described in item 71153;
one test
34.55

71155
Testing for the presence of 2 antibodies by tests mentioned in item 71153
47.45

71156
This item applies to a test described in item 71153 (other than a test described in item 71154) if:
(a) a referring APP has performed the test or tests described in item 71153; and
(b) a receiving APP performs the test or tests described in item 71153;
one test
12.85

71157
Testing for the presence of 3 antibodies by tests mentioned in item 71153
60.30

71159
Testing for the presence of 4 antibodies by tests mentioned in item 71153
73.15

71163
Detection of one of the following antibodies (of one or more class or isotype) in the assessment or diagnosis of coeliac disease or other gluten hypersensitivity syndromes, including a service described in item 71066 (if performed):
(a) antibodies to gliadin;
(b) antibodies to endomysium;
(c) antibodies to tissue transglutaminase;
one test
24.75

71164
Two or more tests mentioned in item 71163, including a service described in item 71066 (if performed)
39.90

71165
Antibodies to tissue antigens (acetylcholine receptor, adrenal cortex, heart, histone, insulin, insulin receptor, intrinsic factor, islet cell, lymphocyte, neuron, ovary, parathyroid, platelet, salivary gland, skeletal muscle, skin basement membrane and intercellular substance, thyroglobulin, thyroid microsome or thyroid stimulating hormone receptor)—detection of one antibody, including quantitation if required
34.55

71166
Detection of 2 antibodies described in item 71165
47.45

71167
Detection of 3 antibodies described in item 71165
60.30

71168
Detection of 4 or more antibodies described in item 71165
73.15

71169
This item applies to a service described in item 71165 if:
(a) a referring APP has not performed the service described in item 71165; and
(b) a receiving APP performs the service described in item 71165
34.55

71170
This item applies to a service described in item 71165 if:
(a) a referring APP has performed the test or tests described in item 71165; and
(b) a receiving APP performs the test or tests described in item 71165;
one test
12.85

71180
Antibody to cardiolipin or beta‑2 glycoprotein I—detection, including quantitation if required; one antibody specificity (IgG or IgM)
34.55

71183
Detection of 2 antibodies described in item 71180
47.45

71186
Detection of 3 or more antibodies described in item 71180
60.30

71189
Detection of specific IgG antibodies to one or more respiratory disease allergens not elsewhere specified
15.50

71192
Two items described in item 71189
28.35

71195
Three or more items described in item 71189
40.05

71198
Estimation of serum tryptase for the evaluation of unexplained acute hypotension or suspected anaphylactic event, assessment of risk in stinging insect anaphylaxis, exclusion of mastocytosis, monitoring of known mastocytosis
40.55

71200
Detection and quantitation, if present, of free kappa and lambda light chains in serum for the diagnosis or monitoring of amyloidosis, myeloma or plasma cell dyscrasias
59.60

71203
Determination of HLAB5701 status by flow cytometry or cytotoxity assay prior to the initiation of Abacavir therapy including item 73323 (if performed)
40.55

Division 2.5—Group P5: tissue pathology
2.5.1  Tests on biopsy material
             (1)  For items in Group P5 (Tissue pathology):
biopsy material means all tissue received by an approved pathology practitioner:
                     (a)  from a medical procedure, or group of medical procedures, performed on a patient at the same time; or
                     (b)  after being expelled spontaneously from a patient.
cytology means microscopic examination of one or more stained preparations of cells separated naturally or artificially from their normal environment by methods recognised as adequate to demonstrate their structure to a degree sufficient to enable an opinion to be formed about whether they are likely to be normal, abnormal but benign, or abnormal and malignant but, in accordance with customary laboratory practice, does not include examination of a blood film or a bone marrow aspirate.
separately identified specimen means an individual specimen collected, identified so that it is clearly distinguished from any other specimen, and sent for testing by or on behalf of the treating practitioner responsible for the procedure in which the specimen was taken.
             (2)  For Group P5, services in Group P6 (Cytology) include any services described in Group P5 on the material submitted for a test in Group P6.
             (3)  For subclause (2), any sample submitted for cytology from which a cell block is prepared does not qualify for a Group P5 item.
             (4)  If more than one of the services mentioned in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838 are performed in a single patient episode, only the fee for the item performed having the highest specified fee is applicable to the services.
             (5)  If more than one histopathological examination is performed on separate specimens, of different complexity levels, from a single patient episode, only the fee for the examination having the highest specified fee is applicable to the examinations.
             (6)  In items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838 a reference to a complexity level is a reference to the level given to a specimen type mentioned in Part 4 of this table.
             (7)  If:
                     (a)  more than one of the services mentioned in items 72846, 72847, 72848, 72849 and 72850; or
                     (b)  more than one of the services mentioned in items 73059, 73060, 73061, 73064 and 73065;
are performed in a single patient episode, only the fee for the item performed having the higher or highest specified fee applies to the services.
 
Group P5—Tissue pathology

Item
Pathology service
Fee ($)

72813
Examination of complexity level 2 biopsy material with one or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions—one or more separately identified specimens
71.50

72816
Examination of complexity level 3 biopsy material with one or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions—one separately identified specimen
86.35

72817
Examination of complexity level 3 biopsy material with one or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions—2 to 4 separately identified specimens
96.80

72818
Examination of complexity level 3 biopsy material with one or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions—5 or more separately identified specimens
107.05

72823
Examination of complexity level 4 biopsy material with one or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions—one separately identified specimen
97.15

72824
Examination of complexity level 4 biopsy material with one or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions—2 to 4 separately identified specimens
141.35

72825
Examination of complexity level 4 biopsy material with one or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions—5 to 7 separately identified specimens
180.25

72826
Examination of complexity level 4 biopsy material with one or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions—8 to 11 separately identified specimens
194.60

72827
Examination of complexity level 4 biopsy material with one or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions—12 to 17 separately identified specimens
208.95

72828
Examination of complexity level 4 biopsy material with one or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions—18 or more separately identified specimens
223.30

72830
Examination of complexity level 5 biopsy material with one or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions—one or more separately identified specimens
274.15

72836
Examination of complexity level 6 biopsy material with one or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions—one or more separately identified specimens
417.20

72838
Examination of complexity level 7 biopsy material with multiple tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy, and professional opinion or opinions—one or more separately identified specimens
466.85

72844
Enzyme histochemistry of skeletal muscle for investigation of primary degenerative or metabolic muscle diseases or of muscle abnormalities secondary to disease of the central or peripheral nervous system—one or more tests
30.75

72846
Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen—one to 3 antibodies except those mentioned in item 72848
59.60

72847
Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen—4 to 6 antibodies
89.40

72848
Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen—one to 3 of the following antibodies:
(a) oestrogen;
(b) progesterone;
(c) c‑erb‑B2 (HER2)
74.50

72849
Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen—7 to 10 antibodies
104.30

72850
Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen—11 or more antibodies
119.20

72851
Electron microscopic examination of biopsy material—one separately identified specimen
184.35

72852
Electron microscopic examination of biopsy material—2 or more separately identified specimens
245.80

72855
Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear—one separately identified specimen
184.35

72856
Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear—2 to 4 separately identified specimens
245.80

72857
Intraoperative consultation and examination of biopsy material by frozen section or tissue imprint or smear—5 or more separately identified specimens
286.75

Division 2.6—Group P6: cytology
2.6.1  Tests on biopsy material
             (1)  For Group P6 (Cytology), services in Group P6 include any services described in Group P5 (Tissue pathology) on the material submitted for a test in Group P6.
             (2)  For subclause (1), any sample submitted for cytology from which a cell block is prepared does not qualify for a Group P5 item.
             (3)  If:
                     (a)  more than one of the services mentioned in items 72846, 72847, 72848, 72849 and 72850; or
                     (b)  more than one of the services mentioned in items 73059, 73060, 73061, 73064 and 73065;
are performed in a single patient episode, only the fee for the item performed having the higher or highest specified fee applies to the services.
             (4)  If more than one of the services mentioned in items 73049, 73051, 73062, 73063, 73066 and 73067 are performed in a single patient episode, the fee for the combined services is:
                     (a)  if services mentioned in 2 items are performed—the higher of the 2 fees specified; or
                     (b)  if services mentioned in more than 2 items are performed—the highest of the fees specified.
 
Group P6—Cytology

Item
Pathology service
Fee ($)

73043
Cytology (including serial examinations) of nipple discharge or smears from skin, lip, mouth, nose or anus for detection of precancerous or cancerous changes—one or more tests
22.85

73045
Cytology (including serial examinations) for malignancy (other than an examination mentioned in item 73053), including any Group P5 service (if performed), one or more tests on:
(a) specimens resulting from washings or brushings from sites not specified in item 73043; or
(b) a single specimen of sputum or urine; or
(c) one or more specimens of other body fluids
48.60

73047
Cytology of a series of 3 sputum or urine specimens for malignant cells
94.70

73049
Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues—one identified site
68.15

73051
Cytology of material obtained directly from a patient at one identified site by fine needle aspiration of solid tissue or tissues if a recognised pathologist:
(a) performs the aspiration; or
(b) attends the aspiration and performs a cytological examination during the attendance
170.35

73053
Cytology of a smear from cervix, where the smear is prepared by direct application of the specimen to a slide, excluding the use of liquid based slide preparation techniques, and the stained smear is microscopically examined by or on behalf of a pathologist—each examination:
(a) for the detection of precancerous or cancerous changes in women with no symptoms, signs or recent history suggestive of cervical neoplasia; or
(b) if a further specimen is taken due to an unsatisfactory smear taken for the purposes of paragraph (a); or
(c) if there is inadequate information provided to use item 73055
19.45

73055
Cytology of a smear from cervix, not associated with item 73053, where the smear is prepared by direct application of the specimen to a slide, excluding the use of liquid based slide preparation techniques, and the stained smear is microscopically examined by or on behalf of a pathologist—each test:
(a) for the management of previously detected abnormalities including precancerous or cancerous conditions; or
(b) for the investigation of women with symptoms, signs or recent history suggestive of cervical neoplasia
19.45

73057
Cytology of a smear from vagina, not associated with item 73053 or 73055, and not to monitor hormone replacement therapy, where the smear is prepared by direct application of the specimen to a slide, excluding the use of liquid based slide preparation techniques, and the stained smear is microscopically examined by or on behalf of a pathologist—each test
19.45

73059
Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051, 73062 and 73063 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen—one to 3 antibodies except those mentioned in item 73061
43.00

73060
Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051, 73062 and 73063 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen—4 to 6 antibodies
57.35

73061
Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051, 73062 and 73063 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen—one to 3 of the following antibodies:
(a) oestrogen;
(b) progesterone;
(c) c‑erb‑B2 (HER2)
51.20

73062
Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues—2 or more separately identified sites
89.00

73063
Cytology of material obtained directly from a patient at one identified site by fine needle aspiration of solid tissue, or tissues, if an employee of an approved pathology authority attends the aspiration for confirmation of sample adequacy
99.35

73064
Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051, 73062 and 73063 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen—7 to 10 antibodies
71.70

73065
Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051, 73062 and 73063 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen—11 or more antibodies
89.00

73066
Cytology of material obtained directly from a patient at 2 or more separately identified sites by fine needle aspiration of solid tissue, or tissues, if a recognised pathologist:
(a) performs the aspiration; or
(b) attends the aspiration and performs cytological examination during the attendance
221.45

73067
Cytology of material obtained directly from a patient at 2 or more separately identified sites by fine needle aspiration of solid tissue, or tissues, if an employee of an approved pathology authority attends the aspiration for confirmation of sample adequacy
129.15

Division 2.7—Group P7: genetics
2.7.1  Haemochromatosis testing
                   For items 73317 and 73318:
elevated serum ferritin, for a patient, means a level of ferritin above the normal reference range for the particular method of assay used to determine the level.
2.7.2  HLA‑B27 typing
                   If a pathology service mentioned in item 73320 or 73321 is rendered as a pathologist‑determinable service, the amount mentioned in the item is not payable for a pathology service mentioned in the item unless the recognised pathologist who renders the service records, in writing, the reasons for rendering the service and the result of the pathology service mentioned in item 71147.
 
Group P7—Genetics

Item
Pathology service
Fee ($)

73287
Study of the whole of every chromosome by cytogenetics or other techniques, performed on one or more of any tissue or fluid except blood (including a service mentioned in item 73293, if performed)—one or more tests
394.55

73289
Study of the whole of every chromosome by cytogenetics or other techniques, performed on blood (including a service mentioned in item 73293, if performed)—one or more tests
358.95

73290
Study of the whole of every chromosome by cytogenetics or other techniques, performed on blood or bone marrow, to diagnose or monitor haematological malignancy (including a service mentioned in item 73287 or 73289, if performed)—one or more tests
394.55

73291
Analysis of one or more chromosome regions, performed on blood or fresh tissue, for specific constitutional genetic abnormalities in:
(a) diagnostic studies of a person with developmental delay, intellectual disability, autism, or at least 2 congenital abnormalities, in whom a study by cytogenetics or other techniques mentioned in item 73287 or 73289 is normal or has not been performed—one or more tests; or
(b) studies of a relative of the person for an abnormality previously identified in the person—one or more tests
230.95

73292
Analysis of chromosomes by genome‑wide microarray, including targeted assessment of specific regions for constitutional genetic abnormalities in diagnostic studies of a person with developmental delay, intellectual disability, autism, or at least 2 congenital abnormalities (including a service mentioned in item 73287, 73289 or 73291, if performed)—one or more tests
589.90

73293
Analysis of one or more regions on all chromosomes, performed on fresh tissue, for specific constitutional genetic abnormalities in diagnostic studies of the products of conception, including exclusion of maternal cell contamination—one or more tests
230.95

73294
Analysis of the PMP22 gene for constitutional genetic abnormalities causing peripheral neuropathy, as:
(a) diagnostic studies of a person with peripheral neuropathy—one or more tests; or
(b) studies of a relative of the person for an abnormality previously identified in the person—one or more tests
230.95

73300
Detection of mutation of the FMR1 gene if:
(a) the patient exhibits intellectual disability, ataxia, neurodegeneration, or premature ovarian failure consistent with an FMR1 mutation; or
(b) the patient has a relative with an FMR1 mutation;
one or more tests
101.30

73305
Detection of a mutation of the FMR1 gene by Southern Blot analysis, if the results of a service performed in item 73300 are inconclusive
202.65

73308
Characterisation of the genotype of a patient for Factor V Leiden gene mutation, or detection of other relevant mutations in the investigation of proven venous thrombosis or pulmonary embolism—one or more tests
36.45

73309
A test described in item 73308 if the test is performed by a receiving APP—one or more tests
36.45

73311
Characterisation of the genotype of a person who is a first degree relative of a person who has been proven to have one or more abnormal genotypes under item 73308—one or more tests
36.45

73312
A test described in item 73311 if the test is performed by a receiving APP—one or more tests
36.45

73314
Characterisation of gene rearrangement or the identification of mutations within a known gene rearrangement in the diagnosis and monitoring of patients with laboratory evidence of:
(a) acute myeloid leukaemia; or
(b) acute promyelocytic leukaemia; or
(c) acute lymphoid leukaemia; or
(d) chronic myeloid leukaemia
230.95

73315
A service described in item 73314 if the characterisation is performed by a receiving APP—one or more tests
230.95

73317
Detection of the C282Y genetic mutation of the HFE gene and, if performed, detection of other mutations for haemochromatosis where:
(a) the patient has an elevated transferrin saturation or elevated serum ferritin on testing of repeated specimens; or
(b) the patient has a first degree relative with haemochromatosis; or
(c) the patient has a first degree relative with homozygosity for the C282Y genetic mutation, or with compound heterozygosity for recognised genetic mutations for haemochromatosis
36.45

73318
A test described in item 73317 if the detection is performed by a receiving APP—one or more tests
36.45

73320
Detection of HLA‑B27 by nucleic acid amplification including a service described in item 71147 unless the service in this item is rendered as a pathologist‑determinable service
40.55

73321
A test described in item 73320 if the detection is performed by a receiving APP—one or more tests
40.55

73323
Determination of HLAB5701 status by molecular techniques prior to the initiation of Abacavir therapy including item 71203 (if performed)
40.55

73324
A test described in item 73323 if rendered by a receiving APP—one or more tests
40.95

73325
Characterisation of mutations in:
(a) the JAK2 gene; or
(b) the MPL gene; or
(c) both genes;
in the diagnostic work‑up, by or on behalf of a specialist or consultant physician, of a patient with clinical and laboratory evidence of:
(d) polycythaemia vera; or
(e) essential thrombocythaemia;
one or more tests
74.50

73326
Characterisation of the gene rearrangement FIP1L1‑PDGFRA in the diagnostic work‑up and management of a patient with laboratory evidence of:
(a) mast cell disease; or
(b) idiopathic hypereosinophilic syndrome; or
(c) chronic eosinophilic leukaemia;
one or more tests
230.95

73327
Detection of genetic polymorphisms in the Thiopurine S‑methyltransferase gene for the prevention of dose‑related toxicity during treatment with thiopurine drugs, including (if performed) any service described in item 65075—one or more tests
51.95

73328
A test of tumour tissue from a patient with locally advanced or metastatic non‑small cell lung cancer requested by, or on behalf of, a specialist or consultant physician to determine if the requirements relating to epidermal growth factor receptor (EGFR) gene status for access to gefitinib under the Pharmaceutical Benefits Scheme (PBS) are fulfilled
397.35

73330
A test of tumour tissue from a patient with metastatic colorectal cancer requested by, or on behalf of, a specialist or consultant physician to determine if the requirements relating to Kirsten ras (KRAS) gene mutation status for access to cetuximab under the Pharmaceutical Benefits Scheme (PBS) are fulfilled
230.95

73332
An in situ hybridization (ISH) test of tumour tissue from a patient with breast cancer requested by, or on the advice of, a specialist or consultant physician who manages the treatment of the patient to determine if the requirements relating to human epidermal growth factor receptor 2 (HER2) gene amplification for access to trastuzumab under the Pharmaceutical Benefits Scheme (PBS) or the Herceptin Program are fulfilled
315.40

73333
Detection of germline mutations of the von Hippel‑Lindau (VHL) gene:
(a) in a patient who has a clinical diagnosis of VHL syndrome and:
(i) a family history of VHL syndrome and one of the following:
(A) haemangioblastoma (retinal or central nervous system);
(B) phaeochromocytoma;
(C) renal cell carcinoma; or
(ii) 2 or more haemangioblastomas; or
(iii) one haemangioblastoma and a tumour or a cyst of:
(A) the adrenal gland; or
(B) the kidney; or
(C) the pancreas; or
(D) the epididymis; or
(E) a broad ligament (other than epididymal and single renal cysts, which are common in the general population); or
(b) in a patient presenting with one or more of the following clinical features suggestive of VHL syndrome:
(i) haemangiblastomas of the brain, spinal cord, or retina;
(ii) phaeochromocytoma;
(iii) functional extra‑adrenal paraganglioma
600.00

73334
Detection of germline mutations of the von Hippel‑Lindau (VHL) gene in biological relatives of a patient with a known mutation in the VHL gene
340.00

73335
Detection of somatic mutations of the von Hippel‑Lindau (VHL) gene in a patient with:
(a) 2 or more tumours comprising:
(i) 2 or more haemangioblastomas, or
(ii) one haemangioblastomas and a tumour of:
(A) the adrenal gland; or
(B) the kidney; or
(C) the pancreas; or
(D) the epididymis; and
(b) no germline mutations of the VHL gene identified by genetic testing
470.00

Division 2.8—Group P8: infertility and pregnancy tests
2.8.1  Limitation on item 73523
                   For any particular patient, item 73523 is applicable not more than 4 times in a 12 month period.
 
Group P8—Infertility and pregnancy tests

Item
Pathology service
Fee ($)

73521
Semen examination for presence of spermatozoa or examination of cervical mucus for spermatozoa (Huhner’s test)
9.70

73523
Semen examination (other than post‑vasectomy semen examination), including:
(a) measurement of volume, sperm count and motility; and
(b) examination of stained preparations; and
(c) morphology; and
(d) (if performed) differential count and one or more chemical tests
41.75

73525
Sperm antibodies—sperm‑penetrating ability—one or more tests
28.35

73527
Human chorionic gonadotrophin (HCG)—detection in serum or urine by one or more methods for diagnosis of pregnancy—one or more tests
10.00

73529
Human chorionic gonadotrophin (HCG), quantitation in serum by one or more methods (except by latex, membrane, strip or other pregnancy test kit) for diagnosis of threatened abortion, or follow up of abortion or diagnosis of ectopic pregnancy, including any services performed in item 73527—one test
28.65

Division 2.9—Group P9: simple basic pathology tests
 
Group P9—Simple basic pathology tests

Item
Pathology service
Fee ($)

73801
Semen examination for presence of spermatozoa
6.90

73802
Leucocyte count, erythrocyte sedimentation rate, examination of blood film (including differential leucocyte count), haemoglobin, haematocrit or erythrocyte count—one test
4.55

73803
Two tests described in item 73802
6.35

73804
Three or more tests described in item 73802
8.15

73805
Microscopy of urine, whether stained or not, or catalase test
4.55

73806
Pregnancy test by one or more immunochemical methods
10.15

73807
Microscopy for wet film other than urine, including any relevant stain
6.90

73808
Microscopy of Gram‑stained film, including (if performed) a service described in item 73805 or 73807
8.65

73809
Chemical tests for occult blood in faeces by reagent stick, strip, tablet or similar method
2.35

73810
Microscopy for fungi in skin, hair or nails—one or more sites
6.90

73811
Mantoux test
11.20

Division 2.10—Group P10: patient episode initiation
2.10.1  Items in Group P10 not to apply in certain circumstances
             (1)  In this Division:
approved collection centre has the meaning given by subsection 23DA(1) of the Act.
institution means a place at which residential accommodation or day care is, or both residential accommodation and day care are, made available to:
                     (a)  disadvantaged children; or
                     (b)  juvenile offenders; or
                     (c)  aged persons; or
                     (d)  chronically ill psychiatric patients; or
                     (e)  homeless persons; or
                      (f)  unemployed persons; or
                     (g)  persons suffering from alcoholism; or
                     (h)  persons addicted to drugs; or
                      (i)  physically or mentally handicapped persons;
but does not include:
                      (j)  a hospital; or
                     (k)  a residential care facility; or
                      (l)  accommodation for aged persons that is attached to a residential care facility or situated within a residential care facility complex.
prescribed laboratory means a laboratory operated by:
                     (a)  the Commonwealth; or
                     (b)  an authority of the Commonwealth; or
                     (c)  a State or internal Territory; or
                     (d)  an authority of a State or internal Territory; or
                     (e)  an Australian tertiary education institution.
residential care facility means a facility in which residential care, within the meaning of section 41‑3 of the Aged Care Act 1997, is provided.
specimen collection centre has the meaning given by subsection 23DA(1) of the Act.
treating practitioner has the same meaning as in paragraph 16A(1)(a) of the Act.
             (2)  If a service mentioned in an item in Group P10 is rendered by, or on behalf of, an approved pathology practitioner who is a recognised pathologist, the relevant item does not apply to the service if:
                     (a)  the service is rendered upon a request made in the course of an out‑patient service at a recognised hospital; or
                     (b)  the service is rendered to a public patient at a recognised hospital.
             (3)  An item in Group P10 does not apply to a pathology service to which subsection 16A(7) of the Act applies.
             (4)  An item in Group P10 does not apply to a pathology service unless at least one item in Groups P1 to P8 also applies to the service.
             (5)  Subject to subclause (6), if one item in Group P10 applies to a patient episode, no other item in the Group applies to the patient episode.
             (6)  If, for the same patient episode:
                     (a)  services mentioned in one or more items in Group P5 and one or more of Groups P1, P2, P3, P4, P6, P7 and P8 are rendered by an approved pathology practitioner in the laboratory of another approved pathology authority; or
                     (b)  services mentioned in one or more items in Group P6 and one or more of Groups P1, P2, P3, P4, P5, P7 and P8 are rendered by an approved pathology practitioner in the laboratory of another approved pathology authority;
the fee mentioned in the applicable item in Group P10 applies to both approved pathology practitioners.
             (7)  If more than one specimen is collected from a person on the same day for the provision of pathology services:
                     (a)  in accordance with more than one request; and
                     (b)  in or by a single approved pathology authority;
the fee mentioned in the applicable item in Group P10 applies once only to the services unless an exemption mentioned in clause 1.2.3, 2.1.1 or 2.2.2 applies or the Minister has made a direction under subsection 4B(3) of the Act.
 
Group P10—Patient episode initiation

Item
Pathology service
Fee ($)

73920
Initiation of a patient episode by collection of a specimen for one or more services (other than those described in item 73922, 73924 or 73926) if the specimen is collected in an approved collection centre that the approved pathology authority operates in the same premises as it operates a category GX or GY pathology laboratory
2.40

73922
Initiation of a patient episode that consists of a service described in item 73053, 73055 or 73057 (in circumstances other than those described in item 73923)
8.20

73923
Initiation of a patient episode that consists of a service described in item 73053, 73055 or 73057 if:
(a) the person is a private patient in a recognised hospital; or
(b) the person receives the service from a prescribed laboratory
2.40

73924
Initiation of a patient episode that consists of one or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838 (in circumstances other than those described in item 73925) from a person who is an inpatient of a hospital
14.65

73925
Initiation of a patient episode that consists of one or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838 if the person is:
(a) a private patient of a recognised hospital; or
(b) a private patient of a hospital who receives the service or services from a prescribed laboratory
2.40

73926
Initiation of a patient episode that consists of one or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838 (in circumstances other than those described in item 73927) from a person who is not a patient of a hospital
8.20

73927
Initiation of a patient episode by a prescribed laboratory that consists of one or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72827, 72828, 72830, 72836 and 72838 from a person who is not a patient of a hospital
2.40

73928
Initiation of a patient episode by collection of a specimen for one or more services (in circumstances other than those described in item 73920, 73922, 73923, 73924, 73925, 73926, 73927 or 73929) if the specimen is collected in an approved collection centre
5.95

73929
Initiation of a patient episode by collection of a specimen for one or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926 or 73927) if the specimen is collected in an approved collection centre by:
(a) an approved pathology practitioner of a prescribed laboratory; or
(b) an employee of an approved pathology authority of a prescribed laboratory
2.40

73930
Initiation of a patient episode by collection of a specimen for one or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926, 73927 or 73931) if the specimen is collected from a person who is an inpatient of a hospital other than a recognised hospital by an approved pathology practitioner or an employee of an approved pathology authority
5.95

73931
Initiation of a patient episode by collection of a specimen for one or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926 or 73927) if the specimen is collected:
(a) from a person who is a private patient of a hospital by an approved pathology practitioner of a prescribed laboratory; or
(b) from a person who is a private patient of a hospital by an employee of an approved pathology authority that operates a prescribed laboratory; or
(c) from a person who is a private patient of a recognised hospital by an approved pathology practitioner of an approved pathology authority; or
(d) from a person who is a private patient of a recognised hospital by an employee of an approved pathology authority
2.40

73932
Initiation of a patient episode by collection of a specimen for one or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926, 73927 or 73933) if the specimen is collected from a person in the place where the person resides, and that place is not an institution, by:
(a) an approved pathology practitioner of an approved pathology authority; or
(b) an employee of an approved pathology authority
10.25

73933
Initiation of a patient episode by collection of a specimen for one or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926 or 73927) if the specimen is collected from a person in the place where the person resides, and that place is not an institution, by:
(a) an approved pathology practitioner of a prescribed laboratory; or
(b) an employee of an approved pathology authority that operates a prescribed laboratory
2.40

73934
Initiation of a patient episode by collection of a specimen for one or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926, 73927 or 73935) if the specimen is collected from a person in an institution by:
(a) an approved pathology practitioner; or
(b) an employee of an approved pathology authority
17.60

73935
Initiation of a patient episode by collection of a specimen for one or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926 or 73927) if the specimen is collected from a person in an institution by:
(a) an approved pathology practitioner of a prescribed laboratory; or
(b) an employee of an approved pathology authority that operates a prescribed laboratory
2.40

73936
Initiation of a patient episode by collection of a specimen for one or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926, 73927 or 73937) if the specimen is collected from the person by the person
5.95

73937
Initiation of a patient episode by collection of a specimen for one or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926 or 73927) if the specimen is collected from the person by the person, and:
(a) the service is performed in a prescribed laboratory; or
(b) the person is a private patient in a recognised hospital
2.40

73938
Initiation of a patient episode by collection of a specimen for one or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926, 73927 or 73939) if the specimen is collected by, or on behalf of, the treating practitioner
7.95

73939
Initiation of a patient episode by collection of a specimen for one or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926 or 73927) if the specimen is collected by, or on behalf of, the treating practitioner and:
(a) the service is performed in a prescribed laboratory; or
(b) the person is a private patient in a recognised hospital
2.40

Division 2.11—Group P11: specimen referred
2.11.1  Items in Group P11 not to apply in certain circumstances
             (1)  An item in Group P11 (Specimen referred) does not apply to a pathology service to which subsection 16A(7) of the Act applies.
             (2)  An item in Group P11 does not apply to a pathology service unless at least one item in Groups P1 to P8 also applies to the service.
             (3)  An item in Group P11 applies only to the approved pathology practitioner or approved pathology authority to whom the specimen mentioned in the item was referred.
             (4)  The fee mentioned in item 73940 applies only once for a single patient episode.
2.11.2  Application of an item in Group P11 to a service excludes certain other items
                   If item 73940 applies to a patient episode, none of the items in Group P10 apply to any pathology service rendered by the approved pathology authority or approved pathology practitioner who claimed item 73940 for the patient episode.
2.11.3  Circumstances in which an item in Group P11 does not apply
             (1)  An item in Group P11 does not apply to a referral if:
                     (a)  a service for the same patient episode has been carried out by the referring approved pathology authority; and
                     (b)  the approved pathology authority to which the referral is made is related to the referring approved pathology authority.
             (2)  An approved pathology authority is related to another approved pathology authority for subclause (1) if:
                     (a)  both approved pathology authorities are employed (including employed under contract) by the same person, whether or not the person is also an approved pathology authority; or
                     (b)  either of the approved pathology authorities is employed (including employed under contract) by the other; or
                     (c)  both approved pathology authorities are corporations and are connected entities within the meaning of the Corporations Act 2001; or
                     (d)  the approved pathology authorities are partners (whether or not either or both of the approved pathology authorities are individuals and whether or not other persons are in partnership with either or both of the approved pathology authorities); or
                     (e)  both approved pathology authorities are operated by the Commonwealth or an authority of the Commonwealth; or
                      (f)  both approved pathology authorities are operated by the same State or internal Territory or an authority of the same State or internal Territory.
             (3)  An item in Group P11 does not apply to a referral if the following common tests are referred either singly or in combination (except if the following items are mentioned in combination with other items not similarly specified): 65060, 65070, 65120, 66500, 66503, 66506, 66509, 66512, 66536, 66596, 69300, 69303, 69333 or 73527.
 
Group P11—Specimen referred

Item
Pathology service
Fee ($)

73940
Receipt of a specimen by an approved pathology practitioner of an approved pathology authority from another approved pathology practitioner of another approved pathology authority
10.25

Division 2.12—Group P12: management of bulk‑billed services
2.12.1  Application of items 74990 and 74991
             (1)  Despite clause 1.2.1:
                     (a)  if the pathology service described in item 74991 is provided to a person, either that item or item 74990, but not both those items, applies to the service; and
                     (b)  if item 74990 or 74991 applies to a pathology service, the fee specified in that item applies in addition to the fee specified in any other item in this table that applies to the service.
             (2)  For items 74990 and 74991:
bulk‑billed, for a pathology service, means:
                     (a)  a medicare benefit is payable to a person for the service; and
                     (b)  under an agreement entered into under section 20A of the Act:
                              (i)  the person assigns to the practitioner by whom, or on whose behalf, the service is provided, his or her right to the payment of the medicare benefit; and
                             (ii)  the practitioner accepts the assignment in full payment of his or her fee for the service provided.
Commonwealth concession card holder means a person who is a concessional beneficiary within the meaning given by subsection 84(1) of the National Health Act 1953.
unreferred service means a pathology service that:
                     (a)  is provided to a person by, or on behalf of, a medical practitioner, being a medical practitioner who is not a consultant physician, or specialist, in any speciality (other than a medical practitioner who is, for the purposes of the Act, both a general practitioner and a consultant physician, or specialist, in a particular speciality); and
                     (b)  has not been referred to the medical practitioner by another medical practitioner or person with referring rights.
             (3)  For item 74991:
ASGC means the document titled Australian Standard Geographical Classification (ASGC) (ABS catalogue number 1216.0), published by the Australian Bureau of Statistics in July 2010.
practice location, for the provision of a pathology service, means the place of practice for which the practitioner by whom, or on whose behalf, the service is provided, has been allocated a provider number by the Chief Executive Medicare.
regional, rural or remote area means an area classified as RRMAs 3‑7 under the Rural, Remote and Metropolitan Areas Classification.
Rural, Remote and Metropolitan Areas Classification has the meaning given by the general medical services table.
SLA means a Statistical Local Area specified in the ASGC.
SSD means a Statistical Subdivision specified in the ASGC.
 
Group P12—Management of bulk‑billed services

Item
Pathology service
Fee ($)

74990
A pathology service to which an item in this table (other than this item or item 74991) applies if:
(a) the service is an unreferred service; and
(b) the service is provided to a person who is under 16 years or is a Commonwealth concession card holder; and
(c) the person is not an admitted patient of a hospital; and
(d) the service is bulk‑billed in respect of the fees for:
(i) this item; and
(ii) the other item in this table applying to the service
7.05

74991
A pathology service to which an item in this table (other than this item or item 74990) applies if:
(a) the service is an unreferred service; and
(b) the service is provided to a person who is under 16 years or is a Commonwealth concession card holder; and
(c) the person is not an admitted patient of a hospital; and
(d) the service is bulk‑billed in respect of the fees for:
(i) this item; and
(ii) the other item in this table applying to the service; and
(e) the service is provided at, or from, a practice location in:
(i) a regional, rural or remote area; or
(ii) Tasmania; or
(iii) a geographical area included in any of the following SSD spatial units:
(A) Beaudesert Shire Part A;
(B) Belconnen;
(C) Darwin City;
(D) Eastern Outer Melbourne;
(E) East Metropolitan Perth;
(F) Frankston City;
(G) Gosford‑Wyong;
(H) Greater Geelong City Part A;
(I) Gungahlin‑Hall;
(J) Ipswich City (Part in BSD);
(K) Litchfield Shire;
(L) Melton‑Wyndham;
(M) Mornington Peninsula Shire;
(N) Newcastle;
(O) North Canberra;
(P) Palmerston‑East Arm;
(Q) Pine Rivers Shire;
(R) Queanbeyan;
(S) South Canberra;
(T) South Eastern Outer Melbourne;
(U) Southern Adelaide;
(V) South West Metropolitan Perth;
(W) Thuringowa City Part A;
(X) Townsville City Part A;
(Y) Tuggeranong;
(Z) Weston Creek‑Stromlo;
(ZA) Woden Valley;
(ZB) Yarra Ranges Shire Part A; or
(iv) the geographical area included in the SLA spatial unit of Palm Island (AC)
10.65

Division 2.13—Group P13: bulk billing incentive for episodes consisting of a P10 service
Note:       The payments mentioned in column 3 of Group P13 are additional payments for bulk billing a patient episode consisting of a pathology service to which a Group P10 item described in column 2 applies.
 
Group P13—Bulk billing incentive for episodes consisting of a P10 service

Item
Pathology service
Fee ($)

74992
A patient episode that:
(a) consists of a pathology service to which item 73920 applies; and
(b) is bulk billed
1.60

74993
A patient episode that:
(a) consists of a pathology service to which item 73922 or 73926 applies; and
(b) is bulk billed
3.75

74994
A patient episode that:
(a) consists of a pathology service to which item 73924 applies; and
(b) is bulk billed
3.25

74995
A patient episode that:
(a) consists of a pathology service to which item 73928, 73930 or 73936 applies; and
(b) is bulk billed
4.00

74996
A patient episode that:
(a) consists of a pathology service to which item 73932 or 73940 applies; and
(b) is bulk billed
3.70

74997
A patient episode that:
(a) consists of a pathology service item 73934 applies; and
(b) is bulk billed
3.30

74998
A patient episode that:
(a) consists of a pathology service to which item 73938 applies; and
(b) is bulk billed
2.00

74999
A patient episode that:
(a) consists of a pathology service to which item 73923, 73925, 73927, 73929, 73931, 73933, 73935, 73937 or 73939 applies; and
(b) is bulk billed
1.60

Part 3—Abbreviations
Note:       A service or drug that is not mentioned in this Part must be written in full.
  
 
Abbreviations

Test
Abbreviation
Item

Abnormal haemoglobins
AH
65117

Acetoacetate
ACAT
66500

Acetylcholine receptor—tissue antigens—antibodies
ARA
71165

Acid phosphatase
ACP
66500

Actinomycetes—microbial antibody testing
ACT
69384

Activated protein C resistance
APC
65142, 65171, 65175–65179

Adenovirus—microbial antibody testing
ADE
69384

Adrenal cortex—tissue antigens—antibodies
ADR
71165

Adrenocorticotrophic hormone (ACTH)
ACTH
66695

AFB microscopy and culture of sputum—one specimen
AFB1
69324

AFB microscopy and culture of sputum—2 specimens
AFB2
69327

AFB microscopy and culture of sputum—3 specimens
AFB3
69330

Alanine aminotransferase
ALT
66500

Albumin
ALB
66500

Alcohol (ethanol)
ETOH
66626, 66800

Aldosterone
ALDS
66695

Alkaline phosphatase
ALP
66500

Alkaline phosphatase—isoenzymes
ALPI
66641

Alpha‑1‑antitrypsin
AAT
66635

Alpha‑fetoprotein
AFP
66650–66653, 66743, 66750, 66751

Aluminium
AL
66825, 66828

Aluminium—renal dialysis
ALR
66671

Amikacin
 
66800

Amino acids
AA
66752

Amiodarone
AMIO
66812

Amitriptyline
AMIT
66812

Ammonia
NH3
66500

Amniotic fluid examination
AFE
66749

Amylase
AMS
66500

Amylobarbitone
AMYL
66812

Androstenedione
ANDR
66695

Angiotensin converting enzyme
ACE
66758

Antibiotic and antimicrobial chemotherapeutic agents—quantitation
QAA
66800, 66812

Antibodies to extractable nuclear antigens—characterisation of antibodies if positive ENA
ENAP
71103

Antibodies to extractable nuclear antigens—detection
ENA
71101

Antibodies to nuclear antigens—detection
ANA
71097

Antibodies to nuclear antigens—quantitation and measurement of DNA binding if positive ANA
ANAP
71099

Antibodies to tissue antigens—acetylcholine receptor
ARA
71165

Antibodies to tissue antigens—adrenal cortex
ADR
71165

Antibodies to tissue antigens—ANCA‑myeloperoxidase
MPO
71153

Antibodies to tissue antigens—ANCA‑PR3
PR3
71153

Antibodies to tissue antigens—anti‑actin
AACT
71119

Antibodies to tissue antigens—anti‑endomysial
EMA
71163

Antibodies to tissue antigens—cardiolipin
ACL
71165

Antibodies to tissue antigens—coeliac disease panel
CLC
71163, 71164

Antibodies to tissue antigens—gastric parietal cell
PCA
71119

Antibodies to tissue antigens—gliadin IgA
GLIA
71163

Antibodies to tissue antigens—gliadin IgG
GLIG
71163

Antibodies to tissue antigens—glomerular basement membrane
GBM
71153

Antibodies to tissue antigens—heart
AHE
71165

Antibodies to tissue antigens—histone
AHI
71165

Antibodies to tissue antigens—insulin receptor antibodies
INSA
71165

Antibodies to tissue antigens—intercellular cement substance of skin
ICCS
71165

Antibodies to tissue antigens—intrinsic factor
AIF
71165

Antibodies to tissue antigens—islet cell
AIC
71165

Antibodies to tissue antigens—Jo‑1
JO1
71119

Antibodies to tissue antigens—keratin
KERA
71119

Antibodies to tissue antigens—liver/kidney microsomes
LKA
71119

Antibodies to tissue antigens—lymphocyte
ALY
71165

Antibodies to tissue antigens—mitochondria
MA
71119

Antibodies to tissue antigens—neuron
ANE
71165

Antibodies to tissue antigens—neutrophil cytoplasm
ANCA
71153

Antibodies to tissue antigens—ovary
AOV
71165

Antibodies to tissue antigens—parathyroid
PTHA
71165

Antibodies to tissue antigens—platelet
APA
71165

Antibodies to tissue antigens—PM‑Sc1
PM1
71119

Antibodies to tissue antigens—reticulin
RCA
71119

Antibodies to tissue antigens—salivary gland
ASG
71165

Antibodies to tissue antigens—Scl‑70
SCL
71119

Antibodies to tissue antigens—skeletal muscle
SLA
71165

Antibodies to tissue antigens—skin basement membrane
SKA
71165

Antibodies to tissue antigens—smooth muscle
SMA
71119

Antibodies to tissue antigens—thyroglobulin
ATG
71165

Antibodies to tissue antigens—thyroid microsome
TMA
71165

Antibodies to tissue antigens—tissue transglutaminase
TTG
71163

Antibodies to tissue antigens—TSH receptor antibody test
TSHA
71165

Antibody testing, microbial (see Microbial)
 
 

Antigen testing, microbial (see Microbial)
 
 

Antithrombin III
ATH
65142, 65171, 65175–65179

Anti‑Xa activity
QAXA
65147

Anus—cytology on specimens from
SMCY
73043

Apolipoprotein B/A1 ratio
APO
66536

Arsenic
AS
66825, 66828

Aspartate aminotransferase
AST
66500

Aspergillus—microbial antibody testing
ASP
69384

Avian precipitins (bird fancier’s disease)—microbial antibody testing
APP
69384

B12 vitamin
B12
66599

Barbiturate
BARB
66800, 66812

Beryllium
BE
66825, 66828

Beta‑2‑microglobulin
BMIC
66629

Beta‑hydroxybutyrate
BHYB
66500

Bicarbonate
HCO3
66500

Bilirubin (all fractions)
BILI
66500

Bilirubin (all fractions)—in urine
UBIL
66500

Bilirubin (all fractions)—neonatal
BILN
66749

Bird fancier’s disease (see avian precipitins)
APP
69384

Blastomyces—microbial antibody testing
BLM
69384

Blood—compatibility testing
XMAT
65099–65108

Blood—culture
BC
69354–69360

Blood—faecal occult
FOB
66764–66770

Blood—film
BF
65066

Blood—full examination
FBE
65070

Blood—gases
GAS
66566

Blood—group and blood group antibodies
BGAB
65096

Blood—group antibodies
BGA
65111

Blood—group systems
BGS
65093

Blood—grouping—ABO and RH (D antigen)
BG
65090

Blood—viscosity
VISC
65060

Body cavities—aspirations of—microscopy and culture of material from
MCPO
69321

Body fluids—cytology
BFCY
73045

Bone—low mineral densities
CBLB
66773

Bone—metabolic bone disease
CBMB
66776

Bone marrow examination—aspirate
BMEA
65087

Bone marrow examination—trephine
BMET
65084

Bordetella pertussis—microbial antibody testing
BOR
69384

Borrelia burgdorferi—microbial antibody testing
BOB
69384

Breath hydrogen test
BHT
66674

Bromide
BRMD
66812

Brucella—microbial antibody testing
BRU
69384

C‑l esterase inhibitor—functional
CEIF
66647

C‑l esterase inhibitor—quantitation
CEIQ
66644

CA‑15.3 antigen
CA15
66650

CA‑19.9 antigen
CA19
66650

CA‑125 antigen
C125
66650

Cadmium
CD
66825, 66828

Caeruloplasmin
CPLS
66632

Calcitonin
CALT
66695

Calcium—ionised
ICA
66584

Calcium (total or corrected for albumin)
CA
66500

Calculus analysis
CALC
66590

Campylobacter jejuni—microbial antibody testing
CAM
69384

Candida—microbial antibody testing
CAN
69384

Carbamazepine (Tegretol)
CARB
66800

Carboxyhaemoglobin
COHB
65117

Carcinoembryonic antigen
CEA
66650

Cardiac enzymes
CE
66506

Cardiolipin—tissue antigens—antibodies
ACL
71165

Catecholamines
CAT
66779

Cell‑mediated immunity—delayed type—hypersensitivity test
CMI
71137

Cell‑mediated immunity in blood
CMIB
69471

Cervix—cytology—abnormalities
CCRA
73055

Cervix—cytology—routine
CCR
73053

Cervix—microscopy and culture of material from
MCGR
69312

Characterisation of antibodies if positive ENA
ENAP
71103

Chemicals, toxic (ingested or absorbed)—assays
DRGO
66623

Chlamydia—investigation by any method
CHLM
69494

Chlamydia—investigation by any method and N gonorrhoea by NAA methods
CHGO
69494

Chlamydia—microbial antibody testing
CHL
69384

Chlamydia—microbial antigen testing
MCCH
69494

Chloral hydrate
CHHY
66812

Chlorazepate
CHZP
66812

Chloride
CL
66500

Chloroquine
CLOQ
66812

Chlorpromazine
CHLO
66812

Cholesterol
CHOL
66500

Cholesterol—HDL
HDLC
66536

Cholinesterase
CHSE
66758

Chorionic gonadotrophin—detection for pregnancy diagnosis
HCGP
73527–73529

Chorionic gonadotrophin—quantitation
HCG
66650–66653, 66750, 66751, 73529

Chromium
CR
66825, 66828

Chromosome identification and banding
 
73287–73289

Chromosome identification—studies—blood
CSB
73289

Chromosome identification—studies—other than blood
CS
73287

Cimetidine
CMTD
66812

Clobazam
CLOB
66812

Clomipramine
CLOM
66812

Clonazepam (Rivotril)
CLON
66812

Clostridium difficile—microbial antigen testing
CLDT
69363

Coagulation factor inhibitors by Bethesda assay
BETH
65159

Coagulation—factors (see individual factors)
 
 

Coagulation—studies
COAG
65120

Coccidioides—microbial antibody testing
CCC
69384

Coeliac antibodies
CLC
71163, 71164

Cold agglutinins
CAG
65114

Collagen—low bone
CBLB
66773

Collagen—metabolic disease
CBMB
66776

Compatibility testing
XMAT
65099–65108

Complement, total haemolytic
COM
71081

Complement, total haemolytic—components C3
C3
71083

Complement, total haemolytic—components C4
C4
71083

Complement, total haemolytic—other components
COMP
71089

Complement, total haemolytic—properdin factor B
PFB
71083

Copper
CU
66819, 66822

Cortisol
CORT
66695

Cortisol in saliva
CORS
66711, 66712

Coxsackie B1‑6—microbial antibody testing
COX
69384

C‑Peptide
CPEP
66695

C‑reactive protein
CRP
66500

Creatine kinase
CK
66500

Creatine kinase—isoenzymes
CKI
66518

Creatine kinase—isoenzymes (electrophoresis)
CKIE
66518

Creatinine
C
66500

Cryofibrinogen—detection and quantitation
CFID
71064

Cryoglobulins—characterisation by electrophoresis and immunoelectrophoresis or immunofixation or isoelectric focusing
RYO
71059

Cryoglobulins—detection and quantitation
CGLD
71064

Cryptococcal antigen—microbial antigen testing
CRYN
69494

Cryptococcus—microbial antibody testing
CRY
69384

CSF antigens—group B streptococcus
STB
69494

CSF antigens—Haemophilus influenzae
HI
69494

CSF antigens—Neisseria meningitidis
NMG
69494

CSF antigens—Streptococcus pneumoniae
SPN
69494

CSF—microscopy and culture of material from
MCPO
69321

Cultural examination of faeces
FCS
69345

Cyclic AMP
CAMP
66695

Cyclosporin A
CLSA
66812

Cystine—qualitative
UCYS
66752

Cystine—quantitative
CYST
66752

Cytology—fine needle aspiration of solid tissues
FNCY
73049

Cytology—fine needle aspiration of solid tissues—aspiration or attendance by a pathologist
FNCP
73051

Cytology—from 3 sputum or urine specimens
SPCY
73047

Cytology—from body fluids, sputum (one specimen), urine, washings or brushings
BFCY
73045

Cytology—from cervix—abnormalities
CCRA
73055

Cytology—from cervix—routine
CCR
73053

Cytology—from skin, nipple discharge, lip, mouth, nose or anus
SMCY
73043

Cytology—from vagina
CVO
73057

Cytomegalovirus—microbial antibody testing
CMV
69384

Cytomegalovirus serology in pregnancy—microbial antibody testing
CMVP
69405–69411

D vitamin
VITD
66608

D‑dimer test
DD
65120

Dehydroepiandrosterone sulphate (DHEAS)
DHEA
66695

Dengue—microbial antibody testing
DEN
69384

11‑Deoxycortisol
DCOR
66695

Desipramine
DESI
66812

Dexamethasone
DXST
66686

Dexamethasone—suppression test
DEXA
66686

DHEAS (Dehydroepiandrosterone sulphate)
DHEA
66695

Diazepam
DIAZ
66812

Differential cell count
DIFF
65070

Digoxin
DIG
66800

Dihydrotestosterone
DHTS
66695

Diphenylhydantoin (Dilantin)
DIL
66812

Diphtheria—microbial antibody testing
DIP
69384

Direct Coombs test
CMBS
65114

Disopyramide (Rythmodan)
DISO
66800

DNA binding—quantitation and measurement if positive ANA
ANAP
71099

DNA (double‑stranded DNA) antibody
DSDNA
71099

Donath Landsteiner antibody test
DLAT
65075

Down’s syndrome and neural tube defects
NTDD
66750, 66751

Doxepin hydrochloride
DOXE
66812

Drugs—abuse treatment programme—assay
DATP
66626

Drugs—inappropriate dosage—assay
DRGO
66623

Drugs—therapeutic—assay (see individual drugs)
 
66800, 66812

Dynamic function tests
GHSE
66686

Ear—microscopy and culture of material from
MCSW
69303

Echinococcus—microbial antibody testing
ECC
69384

Echis test
ECHI
65120

ECHO‑coxsackie group—microbial antibody testing
ECH
69384

Electrolytes
E
66509

Electron microscopy of biopsy material
EM
72851, 72852

Electrophoresis, and immunofixation or immunoelectrophoresis or isoelectric focusing—characterisation of cryoglobulins
RYO
71059

Electrophoresis, and immunofixation or immunoelectrophoresis or isoelectric focusing—characterisation of paraprotein
PRYO
71059

Electrophoresis, to demonstrate—creatine kinase isoenzymes
CKIE
66518

Electrophoresis, to demonstrate—lactate dehydrogenase isoenzymes
LDI
66641

Electrophoresis, to demonstrate—lipoprotein subclasses
LEPG
66539

Electrophoresis, to demonstrate—quantitation of protein classes, or paraprotein
EPPI
71057, 71058

Elements (see individual elements)
 
 

Endomysium antibodies
EMA
71163

Entamoeba histolytica—microbial antibody testing
AMO
69384

Enzyme assays of solid tissue or tissues
ENZS
66683

Enzyme histochemistry of skeletal muscle
EHSK
72844

Eosinophil cationic protein
ECP
71095

Epstein Barr virus—microbial antibody testing
EBV
69472–69474

Erythrocyte—assessment of haemolysis
ERYH
65075

Erythrocyte—assessment of metabolic enzymes
ERYM
65075

Erythrocyte—count
RCC
65070

Erythrocyte—sedimentation rate
ESR
65060

Ethanol (alcohol)
ETOH
66626, 66800

Ethosuximide (Zarontin)
ETHO
66800

Extractable nuclear antigens—detection of antibodies to
ENA
71101

Eye—microscopy and culture of material from
MCSW
69303

Factor II
FII
65150

Factor V
FV
65150

Factor V Leiden mutation
FVLM
73308, 73311

Factor VII
FVII
65150

Factor VIII
VIII
65150

Factor IX
FIX
65150

Factor X
FX
65150

Factor XI
FXI
65150

Factor XII
FXII
65150

Factor XIII
XIII
65150

Factor XIII deficiency test
F13D
65120

Faecal antigen test for Helicobacter pylori
FAHP
69494

Faecal blood
FOB
66764–66770

Faecal fat
FFAT
66674

Faecal fat—haemoglobin
FFH
66764

Faecal fat—reducing substances
FRS
66761

Faeces—culture
FCS
69345

Faeces—microscopy for parasites
OCP
69336–69339

Ferritin (see also Iron studies)
FERR
66593

Fibrin monomer
FM
65120

Fibrinogen
FIB
65120

Fibrinogen—degradation products
FDP
65120

Fitzgerald factor
FGF
65150

Flecainide
FLEC
66812

Fletcher factor
FF
65150

Fluorescent treponemal antibody—absorption test (FTA‑ABS)—microbial antibody testing
FTA
69384

Fluoxetine
FLUX
66812

Foetal red blood cells—Kliehauer
KLEI
65162

Folate—red cell
RCF
66599

Follicle stimulating hormone (FSH)
FSH
66695

Fragile X
FXS
73300, 73305

Frozen section diagnosis of biopsy material
FS
72855, 72856

Fructosamine
FRUC
66557

Full blood examination
FBE
65070

Gamma glutamyl transpeptidase
GGT
66500

Gastric parietal cell—tissue antigens—antibodies
PCA
71119

Gastrin
GAST
66695

Gentamicin
 
66800

Gliadin IgA—tissue antigens—antibodies
GLIA
71163

Globulin
GLOB
66500

Glomerular basement membrane—tissue antigens—antibodies
GBA
71165

Glucagon
GLGO
66695

Glucose
GLUC
66500

Glucose—tolerance test
GTT
66542

Glycosylated haemoglobin (Hb Alc)
GHB
66551

Gold
AU
66825, 66828

Group B streptococcus—CSF antigens
STB
69494

Group B streptococcus—microbial antigen testing
STB
69494

Group P9—simple basic pathology tests
 
73801–73811

Growth hormone
GH
66695

Growth hormone—stimulation by exercise or L‑dopa
GHSE
66686

Growth hormone—suppression by dexamethasone or glucose
GHSG
66686

Haematocrit
HCT
65070

Haemochromatosis
FEUP
73317

Haemoglobin
HB
65060

Haemoglobinopathy tests
HMGP
65081

Haemophilus influenzae—CSF antigens
HI
69494

Haemophilus influenzae—microbial antibody testing
HUS
69384

Haemophilus influenzae—microbial antigen testing
HI
69494

Haloperidol
HALO
66812

Haptoglobins
HGLB
66632

HDL cholesterol
HDLC
66536

Heart—tissue antigens—antibodies
AHE
71165

Heparin—test
HEPR
65144

Hepatitis B or C confirmatory test
HSVP
69484

Hepatitis C—detection
RNAC
69499

Hepatitis C—genotype
GHCV
69491

Hepatitis C—quantitation
THCV
69488

Hepatitis investigation—3 markers
HEP3
69481

Hepatitis serology—in pregnancy
HEPP
69405–69413

Hepatitis status or carriage—one marker
HEP1
69475

Hepatitis status or carriage—2 markers
HEP2
69478

Hepatitis status or carriage—3 markers
HEP3
69481

Herpes simplex virus—direct detection from clinical material
HSV
69494

Herpes simplex virus—investigation by culture
HSVC
69494

Herpes simplex virus—microbial antibody testing
HPA
69384

Herpes simplex virus—microbial antigen testing
HSV
69494

Heterophil antibodies
IM
65114

HIAA (hydroxyindoleacetic acid)
HIAA
66779

Histamine
HIAM
66779

Histone—tissue antigens—antibodies
AHI
71165

Histopathology of biopsy material
HIST
72813–72836

Histoplasma—microbial antibody testing
HIP
69384

HIV—antiretroviral therapy
TVLT
69381

HIV—cerebrospinal fluid
CVLT
69382

HIV—monitoring
MVLT
69378

HLA typing—HLA class 1
HLA1
71149

HLA typing—HLA class 2
HLA2
71151

HLA typing—HLA‑B27
HLAB
71147

HMMA (hydroxy‑3‑methoxymandelic acid, previously known as VMA)
HMMA
66779

HMPG (hydroxy‑methoxy phenylethylene glycol)
HMPG
66779

Homovanillic acid
HVA
66779

Hormone receptor assay—breast
HRA
66662

Hormone receptor assay—ovary
HRO
66662

Hormones—11 deoxycortisol
DCOR
66695

Hormones—adrenocorticotrophic hormone
ACTH
66695

Hormones—aldosterone
ALDS
66695

Hormones and hormone binding proteins (see individual hormones and proteins)
 
66695

Hormones—androstenedione
ANDR
66695

Hormones—calcitonin
CALT
66695

Hormones—cortisol
CORT
66695

Hormones—C‑Peptide
CPEP
66695

Hormones—cyclic AMP
CAMP
66695

Hormones—dehydroepiandrosterone sulphate (DHEAS)
DHEA
66695

Hormones—dihydrotestosterone
DHTS
66695

Hormones—follicle stimulating hormone
FSH
66695

Hormones—gastrin
GAST
66695

Hormones—glucagon
GLGO
66695

Hormones—growth hormone
GH
66695

Hormones—growth hormone—stimulation by exercise or L‑dopa
GHSE
66686

Hormones—growth hormone—suppression by dexamethasone or glucose
GHSG
66686

Hormones—hormone receptor assay—breast
HRA
66662

Hormones—hormone receptor assay—ovary
HRO
66662

Hormones—human chorionic gonadotrophin—detection for pregnancy diagnosis
HCGP
73527, 73529

Hormones—human chorionic gonadotrophin—quantitation
HCG
66650–66653, 66750, 66751, 73529

Hormones—hydroxyprogesterone
OHP
66695

Hormones—insulin
INS
66695

Hormones—luteinizing hormone
LH
66695

Hormones—oestradiol
E2
66695

Hormones—oestriol
E3
66750, 66751

Hormones—oestrone
E1
66695

Hormones—parathyroid hormone
PTH
66695

Hormones—progesterone
PROG
66695

Hormones—prolactin
PROL
66695

Hormones—renin
REN
66695

Hormones—sex hormone binding globulin
SHBG
66695

Hormones—somatomedin
SOMA
66695

Hormones—stimulation by exercise or L‑dopa
GHSE
66686

Hormones—suppression by dexamethasone or glucose
GHSG
66686

Hormones—testosterone
TES
66695

Hormones—urine steroid fraction or fractions
USF
66695

Hormones—vasoactive intestinal peptide
VIP
66695

Hormones—vasopressin
ADH
66695

Huhner’s test
HT
73521

Human chorionic gonadotrophin—detection for pregnancy diagnosis
HCGP
73527, 73529

Human chorionic gonadotrophin—quantitation
HCG
66650–66653, 66750, 66751, 73529

Human papillomaviruses
HPV
69418

HVA (homovanillic acid)
HVA
66779

Hydatid—microbial antibody testing
HYD
69384

Hydroxy‑3‑methoxymandelic acid (previously known as VMA)
HMMA
66779

Hydroxychloroquine
HOCQ
66812

Hydroxyindoleacetic acid
HIAA
66779

Hydroxy methoxy phenylethylene glycol
HMPG
66779

Hydroxyprogesterone
OHP
66695

Hydroxyproline
HYDP
66752

Imipramine
IMIP
66812

Immediate frozen section diagnosis of biopsy material
FS
72855–72856

Immunocyto. one‑3 antibodies
ICC
73059, 73061

Immunocyto. 4+ antibodies
ICC1
73060

Immunoelectrophoresis and electrophoresis—characterisation of cryoglobulins
RYO
71059

Immunoelectrophoresis and electrophoresis—characterisation of paraprotein
PPRO
71059

Immunoglobulins—A
IGA
71066

Immunoglobulins—D
IGD
71074

Immunoglobulins—E (total)
IGE
71075–71079

Immunoglobulins—G
IGG
71068

Immunoglobulins—G, 4 subclasses
SIGG
71073

Immunoglobulins—M
IGM
71072

Immunohistochemical investigation of biopsy material
HIS
72846–72848

Infectious mononucleosis
IM
69384

Influenza A—microbial antibody testing
FLA
69384

Influenza B—microbial antibody testing
FLB
69384

Insulin
INS
66695

Insulin receptor antibodies—tissue antigens—antibodies
INSA
71165

Insulin—tissue antigens—antibodies
AINS
71165

Intercellular cement substance of skin—tissue antigens—antibodies
ICCS
71165

Intestinal disaccharidases
INTD
66680

Intrinsic factor—tissue antigens—antibodies
AIF
71165

Iron studies (iron, transferrin and ferritin)
IS
66596

Islet cell—tissue antigens—antibodies
AIC
71165

Isoelectric focusing and electrophoresis—characterisation of cryoglobulins
RYO
71059

Isoelectric focusing and electrophoresis—characterisation of paraprotein
PPRO
71059

Jo—1—tissue antigens—antibodies
JO1
71119

Keratin—tissue antigens—antibodies
KERA
71119

Kleihauer test
KLEI
65162

Lactate
LACT
66500

Lactate—dehydrogenase
LDH
66500

Lactate—dehydrogenase isoenzymes
LDI
66641

Lamellar body phospholipid
LBPH
66749

Lead
PB
66665

Lecithin/sphingomyelin ratio (amniotic fluid)
LS
66749

Legionella pneumophila—serogroup 1—microbial antibody testing
LP1
69384

Legionella pneumophila—serogroup 2—microbial antibody testing
LP2
69384

Leishmaniasis—microbial antibody testing
LEI
69384

Leptospira—microbial antibody testing
LEP
69384

Leucocyte count
WCC
65070

Leucocyte count—3 surface markers—blood, CSF, serous fluid
LMH3
71139

Leucocyte count—3 surface markers—tissue
LMT3
71141

Leucocyte count—6 surface markers—blood, CSF, serous fluid and tissue(s)
LMHT
71145

Leucocyte count—6 surface markers—blood, CSF, serous fluid or tissue
LM6
71143

Leucocyte count—CD34 surface marker only—blood
LMCD34
71146

Lignocaine
LIGN
66800

Lip—cytology on specimens from
SMCY
73043

Lipase
LIP
66500

Lipid studies
FATS
66500

Lipoprotein subclasses—electrophoresis
LEPG
66539

Listeria—microbial antibody testing
LIS
69384

Lithium
LI
66800

Liver function tests
LFT
66515

Liver/kidney microsomes—tissue antigens—antibodies
LKA
71119

Lupus anticoagulant
LUPA
65137, 65142, 65175–65179

Luteinizing hormone
LH
66695

Lymphocyte—tissue antigens—antibodies
ALY
71165

Lymphocytes—functional tests—one test
LF1
71127

Lymphocytes—functional tests—2 tests
LF2
71129

Lymphocytes—functional tests—3 tests
LF3
71131

Magnesium
MG
66500

Mammary serum antigen
MSA
66650

Manganese
MN
66819, 66822

Mantoux test
MANT
73811

Measles—microbial antibody testing
MEA
69384

Mercury
HG
66825, 66828

Metabolic bone disease
CBMB
66776

Metanephrines
MNEP
66779

Methadone
MTDN
66812

Methaemalbumin detection (Schumm’s test)
SCHM
65117

Methotrexate
MTTA
66812

Methsuximide
MSUX
66812

Methylphenobarbitone
MPBT
66812

Metronidazole
MRDZ
66812

Mexiletine (Mexitil)
MEX
66812

Mianserin
MIAS
66812

Microalbumin
MALB
66560

Microbial antibody testing—actinomycetes
ACT
69384

Microbial antibody testing—adenovirus
ADE
69384

Microbial antibody testing—aspergillus
ASP
69384

Microbial antibody testing—avian precipitins (bird fancier’s disease)
APP
69384

Microbial antibody testing—Blastomyces
BLM
69384

Microbial antibody testing—Bordetella pertussis
BOR
69384

Microbial antibody testing—Borrelia burgdorferi
BOB
69384

Microbial antibody testing—Brucella
BRU
69384

Microbial antibody testing—Campylobacter jejuni
CAM
69384

Microbial antibody testing—Candida
CAN
69384

Microbial antibody testing—Chlamydia
CHL
69384

Microbial antibody testing—Coccidioides
CCC
69384

Microbial antibody testing—Coxsackie B1‑6
COX
69384

Microbial antibody testing—Cryptococcus
CRY
69384

Microbial antibody testing—cytomegalovirus
CMV
69384

Microbial antibody testing—cytomegalovirus serology in pregnancy
CMVP
69384

Microbial antibody testing—dengue
DEN
69384

Microbial antibody testing—diphtheria
DIP
69384

Microbial antibody testing—echinococcus
ECC
69384

Microbial antibody testing—echo‑coxsackie group
ECH
69384

Microbial antibody testing—Entamoeba histolytica
AMO
69384

Microbial antibody testing—Epstein Barr virus
EBV
69472–69474

Microbial antibody testing—fluorescent treponemal antibody—absorption test (FTA‑ABS)
FTA
69384

Microbial antibody testing—Haemophilus influenzae
HUS
69384

Microbial antibody testing—herpes simplex virus
HPA
69384

Microbial antibody testing—Histoplasma
HIP
69384

Microbial antibody testing—Human Immunodeficiency Virus
 
69384

Microbial antibody testing—hydatid
HYD
69384

Microbial antibody testing—infectious mononucleosis
IM
69384

Microbial antibody testing—influenza A
FLA
69384

Microbial antibody testing—influenza B
FLB
69384

Microbial antibody testing—Legionella pneumophila—serogroup 1
LP1
69384

Microbial antibody testing—Legionella pneumophila—serogroup 2
LP2
69384

Microbial antibody testing—leishmaniasis
LEI
69384

Microbial antibody testing—Leptospira
LEP
69384

Microbial antibody testing—Listeria
LIS
69384

Microbial antibody testing—measles
MEA
69384

Microbial antibody testing—Micropolyspora faeni
MIC
69384

Microbial antibody testing—mumps
MUM
69384

Microbial antibody testing—Murray Valley encephalitis
MVE
69384

Microbial antibody testing—Mycoplasma pneumoniae
MYC
69384

Microbial antibody testing—Neisseria meningitidis
MEN
69384

Microbial antibody testing—Newcastle disease
NCD
69384

Microbial antibody testing—parainfluenza 1
PF1
69384

Microbial antibody testing—parainfluenza 2
PF2
69384

Microbial antibody testing—parainfluenza 3
PF3
69384

Microbial antibody testing—paratyphi
PTY
69384

Microbial antibody testing—pertussis
PER
69384

Microbial antibody testing—poliomyelitis
PLO
69384

Microbial antibody testing—Proteus OX 19
POX
69384

Microbial antibody testing—Proteus OXK
POK
69384

Microbial antibody testing—Q fever
QFF
69384

Microbial antibody testing—rapid plasma reagin test
RPR
69384

Microbial antibody testing—respiratory syncytial virus
RSV
69384

Microbial antibody testing—Ross River virus
RRV
69384

Microbial antibody testing—rubella
RUB
69384

Microbial antibody testing—Salmonella typhi (H)
SAH
69384

Microbial antibody testing—Salmonella typhi (O)
SAO
69384

Microbial antibody testing—Schistosoma
STO
69384

Microbial antibody testing—streptococcal serology—anti‑DNASE B titre
ADNB
69384

Microbial antibody testing—streptococcal serology—anti‑streptolysin O titre
ASOT
69384

Microbial antibody testing—Streptococcus pneumoniae
PCC
69384

Microbial antibody testing—tetanus
TET
69384

Microbial antibody testing—Thermoactinomyces vulgaris
THE
69384

Microbial antibody testing—thermopolyspora
TPS
69384

Microbial antibody testing—Toxocara
TOC
69384

Microbial antibody testing—Toxoplasma
TOX
69384

Microbial antibody testing—TPHA (Treponema pallidum haemagglutination test)
TPHA
69384

Microbial antibody testing—Treponema pallidum haemagglutination test
TPHA
69384

Microbial antibody testing—trichinosis
TOS
69384

Microbial antibody testing—typhus, Weil‑Felix
TYP
69384

Microbial antibody testing—Varicella zoster
VCZ
69384

Microbial antibody testing—VDRL (Venereal Disease Research Laboratory)
VDRL
69384

Microbial antibody testing—Yersinia enterocolitica
YER
69384

Microbial antigen testing—Chlamydia
MCCH
69494

Microbial antigen testing—Clostridium difficile
CLDT
69363

Microbial antigen testing—group B streptococcus
STB
69494

Microbial antigen testing—Haemophilus influenzae
HI
69494

Microbial antigen testing—herpes simplex virus
HSV
69494

Microbial antigen testing—Neisseria gonorrhoeae
GON
69494

Microbial antigen testing—Neisseria meningitidis
NMG
69494

Microbial antigen testing—respiratory syncytial virus
RSVN
69494

Microbial antigen testing—Streptococcus pneumonia
SPN
69494

Microbial antigen testing—Varicella zoster
VCZN
69494

Micropolyspora faeni
MIC
69384

Microscopic examination of—faeces for parasites
OCP
69336–36939

Microscopic examination of—wet film material other than blood
MWFM
69300

Microscopy and culture of—material from nose, throat, eye or ear
MCSW
69303

Microscopy and culture of—material from skin
MCSK
69309

Microscopy and culture of—postoperative wounds, aspirates of body cavities
MCPO
69321

Microscopy and culture of—specimens of sputum
MCSP
69318

Microscopy and culture of—specimens of sputum, urine or other body fluids for mycobacteria—one specimen
AFB1
69324

Microscopy and culture of—specimens of sputum, urine or other body fluids for mycobacteria—2 specimens
AFB2
69327

Microscopy and culture of—specimens of sputum, urine or other body fluids for mycobacteria—3 specimens
AFB3
69330

Microscopy and culture of—superficial sites
MCSS
69306

Microscopy and culture of—urethra, vagina, cervix or rectum
MCGR
69312

Microscopy and culture to detect pathogenic micro‑organisms including Chlamydia
MCCH
69494

Microscopy, culture, identification and sensitivity of urine
UMCS
69333

Mitochondria—tissue antigens—antibodies
MA
71119

Mouth—cytology on specimens from
SMCY
73043

Mumps—microbial antibody testing
MUM
69384

Murray Valley encephalitis—microbial antibody testing
MVE
69384

Mycobacteria microscopy and culture of sputum—one specimen
AFB 1
69324

Mycobacteria microscopy and culture of sputum—2 specimens
AFB 2
69327

Mycobacteria microscopy and culture of sputum—3 specimens
AFB 3
69333

Mycoplasma pneumoniae—microbial antibody testing
MYC
69384

Myoglobin
MYOG
66518

N‑acetyl procainamide
NAPC
66812

Neisseria gonorrhoeae by NAA techniques and chlamydia by any method
CHGO
69494

Neisseria gonorrhoeae—microbial antigen testing
GON
69494

Neisseria meningitidis—antigens
NMG
69494

Neisseria meningitidis—microbial antibody testing
MEN
69384

Neisseria meningitidis—microbial antigen testing
NMG
69494

Netilmicin
 
66800

Neural tube defects and Down’s syndrome
NTDD
66750, 66751

Neuron—tissue antigens—antibodies
ANE
71165

Neutrophil cytoplasm—tissue antigens—antibodies
ANCA
71165

Neutrophil functions
NFT
71135

Newcastle disease—microbial antibody testing
NCD
69384

Nickel
NI
66825, 66828

Nipple discharge—cytology on specimens from
SMCY
73043

Nitrazepam
NITR
66812

Nordothiepin
NDIP
66812

Norfluoxetine
NFLE
66812

Nortriptyline
NORT
66812

Nose—cytology on specimens from
SMCY
73043

Nose—microscopy and culture of material from
MCSW
69303

Nuclear antigens—detection of antibodies to
ANA
71097

Oestradiol
E2
66695

Oestriol
E3
66750, 66751

Oestrone
E1
66695

Oligoclonal proteins
OGP
71062

Op/biopsy specimens—microscopy and culture of material from
MCPO
69321

Oral glucose challenge test—gestational diabetes
OGCT
66545

Oral glucose tolerance test—gestational diabetes
GTTP
66542

Osmolality, serum or urine
OSML
66563

Ovary—tissue antigens—antibodies
AOV
71165

Oxalate
OXAL
66752

Oxazepam
OXAZ
66812

PAA (phenyl acetic acid)
PAA
66779

Palmitic acid in amniotic fluid
PALM
66749

Pap smear
CCR
73053

Papanicolaou test
CCR
73053

Paracetamol
PARA
66800

Parainfluenza 1—microbial antibody testing
PF1
69384

Parainfluenza 2—microbial antibody testing
PF2
69384

Parainfluenza 3—microbial antibody testing
PF3
69384

Paraprotein characterisation—by electrophoresis and immunoelectrophoresis or immunofixation or isoelectric focusing
PPRO
71059

Paraprotein characterisation—on concurrently collected serum or urine
PPSU
71060

Paraprotein quantitation—by electrophoresis
EPPI
71057

Paraquat
PARQ
66812

Parasites—microscopic examination of faeces
OCP
69336–69339

Parathyroid hormone (PTH)
PTH
66695

Parathyroid—tissue antigens—antibodies
PTHA
71165

Paratyphi—microbial antibody testing
PTY
69384

Partial thromboplastin time
PTT
65120

Patient episode initiation fees
PEI
73922–73939

Pentobarbitone
PENT
66812

Perhexiline
PHEX
66812

Pertussis—microbial antibody testing
PER
69384

Phenobarbitone
PHBA
66800

Phensuximide
PHEN
66812

Phenylacetic acid
PAA
66779

Phenytoin
PHEY
66800

Phosphate
PHOS
66500

Phosphatidylglycerol
PTGL
66749

Platelet—aggregation
PLTG
65144

Platelet—count
PLTC
65070

Platelet—tissue antigens—antibodies
APA
71165

PM‑Sc1—tissue antigens—antibodies
PM1
71119

Poliomyelitis—microbial antibody testing
PLO
69384

Porphobilinogen in urine
UPG
66782

Porphyrins in urine—qualitative test
UPR
66782

Porphyrins—quantitative test, one or more fractions
PR
66785

Potassium
K
66500

Prealbumin
PALB
66632

Prednisolone
PRED
66812

Pregnancy serology—one test
MSP1
69405

Pregnancy serology—2 tests
MSP2
69408

Pregnancy serology—3 tests
MSP3
69411

Pregnancy serology—4 tests
MSP4
69413

Pregnancy testing
 
73806

Pregnancy testing—diagnosis of Down’s syndrome and neural tube defect
NTDD
66750, 66751

Pregnancy testing—HCG detection
HCG
73527, 73529

Pregnancy testing—HCG quantitation
HCG
73529

Primidone
PRIM
66800

Procainamide
PCAM
66800

Progesterone
PROG
66695

Prolactin
PROL
66695

Propranolol
PPNO
66812

Prostate specific antigen
PSA
66655–66659

Protein—C
PROC
65142, 65171, 65175–65179

Protein—S
PROS
65142, 65171, 65175–65179

Protein, quantitation of—alpha fetoprotein
AFP
66650–66653, 66743, 66750, 66751

Protein, quantitation of—alpha‑l‑antitrypsin
AAT
66635

Protein, quantitation of—beta‑2‑microglobulin
BMIC
66629

Protein, quantitation of—C‑l esterase inhibitor
CEI
66644

Protein, quantitation of—caeruloplasmin
CPLS
66632

Protein, quantitation of—classes or presence and amount of paraprotein by electrophoresis
EPPI
71057, 71058

Protein, quantitation of—ferritin (see also Iron studies)
FERR
66593

Protein, quantitation of—for Down’s syndrome and neural tube defect testing
NTDD
66750, 66751

Protein, quantitation of—haptoglobins
HGLB
66632

Protein, quantitation of—microalbumin
MALB
66560

Protein, total—quantitation of
PROT
66500

Proteus OX 19—microbial antibody testing
POX
69384

Proteus OXK—microbial antibody testing
POK
69384

Prothrombin gene mutation
PGM
73308, 73311

Prothrombin time
PT
65120

Pyruvate
PVTE
66500

Q fever—microbial antibody testing
QFF
69384

Quinalbarbitone
QUIB
66812

Quinidine
QUIN
66800

Quinine
QNN
66812

Rapid plasma reagin test—microbial antibody testing
RPR
69384

RAST
RAST
71079

Rectum—microscopy and culture of material from
MCGR
69312

Red blood cells—Kleihauer
KLEI
65162

Red cell folate and serum B12
B12F
66602

Red cell folate and serum B12 and serum folate if required
B12F
66602

Red cell folate and serum folate
RCF
66599

Red cell porphyrins—qualitative test
RCP
66782

Referred specimen fee
 
73940

Renin
REN
66695

Reptilase test
REPT
65120

Respiratory syncytial virus—microbial antibody testing
RSV
69384

Respiratory syncytial virus—microbial antigen testing
RSVN
69494

Reticulin—tissue antigens—antibodies
RCA
71119

Reticulocyte count
RETC
65072

Rheumatoid factor
RF
71106

Rheumatoid factor—quantitation
RFQ
71106

Ross River virus—microbial antibody testing
RRV
69384

RSV (respiratory syncytial virus)—microbial antibody testing
RSV
69384

RSV (respiratory syncytial virus)—microbial antigen testing
RSVN
69494

Rubella—serology
RUB
69384

Salicylate (aspirin)
SALI
66800

Salivary gland—tissue antigens—antibodies
ASG
71165

Salmonella typhi (H)—microbial antibody testing
SAH
69384

Salmonella typhi (O)—microbial antibody testing
SAO
69384

Schistosoma—microbial antibody testing
STO
69384

Scl‑70—tissue antigens—antibodies
SCL
71119

Selenium
SE
66819, 66822

Semen examination
SEE
73523

Semen examination—for spermatozoa (post vasectomy)
SES
73521

Serology—in pregnancy (see Pregnancy serology)
 
 

Serotonin
5HT
66779

Serum—B12
B12
66599

Serum—folate (with B12)
B12
66599

Serum—folate (with B12 red cell folate)
B12F
66602

Sex hormone binding globulin
SHBG
66695

Skeletal muscle—tissue antigens—antibodies
SLA
71165

Skin—cytology
SMCY
73043

Skin—microscopy and culture of material from
MCSS
69306

Skin—microscopy, culture and Chlamydia of material from
MCSK
69309

Skin basement membrane—tissue antigens—antibodies
SKA
71165

Smooth muscle—tissue antigens—antibodies
SMA
71119

Snake venom
HISS
66623

Sodium
NA
66500

Solid tissue or tissues—chemical assays
ENZS
66683

Solid tissue or tissues—cytology of fine needle aspiration
FNCY
73049

Solid tissue or tissues—cytology of fine needle aspiration by, or in presence of pathologist
FNCP
73051

Somatomedin
SOMA
66695

Sotalol
SALL
66812

Specific IgE or IgG antibodies
RAST
71079

Specimen referred fee
 
73940

Sperm antibodies
SAB
73525

Sperm antibodies—penetrating ability
SPA
73525

Sputum—cytology—one specimen
BFCY
73045

Sputum—cytology—3 specimens
SPCY
73047

Sputum—for mycobacteria—one specimen
AFB1
69324

Sputum—for mycobacteria—2 specimens
AFB2
69327

Sputum—for mycobacteria—3 specimens
AFB3
69330

Sputum—microscopy and culture of specimens
MCSP
69318

Stelazine
STEL
66812

Steroid fraction or fractions in urine
USF
66695

Streptococcal serology—anti‑DNASE B titre—microbial antibody testing
ADNB
69384

Streptococcal serology—anti‑streptolysin O titre—microbial antibody testing
ASOT
69384

Streptococcus—Group B
STB
69494

Streptococcus pneumoniae—CSF antigens
SPN
69494

Streptococcus pneumoniae—microbial antibody testing
PCC
69384

Streptococcus pneumoniae—microbial antigen testing
SPN
69494

Strontium
SR
66825, 66828

Stypven test
STYP
65120

Sugar water test
SWT
65075

Sulthiame (Ospolot)
SUL
66812

Supplementary testing for Hepatitis C antibodies
HCST
69441

Syphilis serology
STS
69387

Testosterone
TES
66695

Tetanus—microbial antibody testing
TET
69384

Thalassaemia studies
TS
65078

Theophylline
THEO
66800

Thermoactinomyces vulgaris—microbial antibody testing
THE
69384

Thermopolyspora—microbial antibody testing
TPS
69384

Thiopentone
TOPO
66812

Thioridazine
THIO
66812

Throat—microscopy and culture of material from
MCSW
69303

Thrombin time
TT
65120

Thrombophilia testing (see individual thrombophilia tests)
 
 

Thyroglobulin
TGL
66650

Thyroglobulin—tissue antigens—antibodies
ATG
71165

Thyroid function tests (including TSH)
TFT
66719

Thyroid microsome—tissue antigens—antibodies
TMA
71165

Thyroid stimulating hormone (if requested on its own, or as a preliminary test to thyroid function testing)
TSH
66716

Thyroid stimulating hormone (if requested with other hormones referred to in item 66695)
TSH
66722–66734

Tissue transglutaminase antibodies
TTG
71163

Tobramycin
 
66800

Total protein
PROT
66500

Toxocara—microbial antibody testing
TOC
69384

Toxoplasma—microbial antibody testing
TOX
69384

Treponema pallidum haemagglutination test—microbial antibody testing
TPHA
69384

Trichinosis—microbial antibody testing
TOS
69384

Triglycerides
TRIG
66500

Trimipramine
TRIM
66812

Troponin
TROP
66518

Tryptic activity in faeces
TAF
66677

TSH receptor antibody test—tissue antigens—antibodies
TSHA
71165

Tuberculosis
MANT
73811

Tumour markers—CA‑15.3 antigen
CA15
66650

Tumour markers—CA‑19.9 antigen
CA19
66650

Tumour markers—CA‑125 antigen
C125
66650

Tumour markers—carcinoembryonic antigen
CEA
66650

Tumour markers—mammary serum antigen
MSA
66650

Tumour markers—prostate specific antigen
PSA
66656

Tumour markers—prostatic acid phosphatase—one or more fractions
ACP
66656

Tumour markers—thyroglobulin
TGL
66650

Typhus, Weil‑Felix—microbial antibody testing
TYP
69384

Urate
URAT
66500

Urea
U
66500

Urea, electrolytes, creatinine
U&E
66515

Urethra—microscopy and culture of material from
MCGR
69312

Urine—acidification test
UAT
66587

Urine—catalase test
UCAT
73805

Urine—cystine (cysteine)
UCYS
66782

Urine—cytology—on one specimen
BFCY
73045

Urine—cytology—on 3 specimens
SPCY
73047

Urine—haemoglobin
UHB
66782

Urine—microscopy, culture, identification and sensitivity
UMCS
69333

Urine—porphobilinogen
UPG
66782

Urine—porphyrins—qualitative test
UPR
66782

Urine—steroid fraction or fractions
USF
66695

Urine—urobilinogen
UUB
66782

Vagina—cytology on specimens from
CVO
73057

Vagina—microscopy and culture of material from
MCGR
69312

Valproate (Epilim)
VALP
66800

Vancomycin
VAN
66800

Varicella zoster—microbial antibody testing
VCZ
69384

Varicella zoster—microbial antigen testing
VCZN
69494

Vasoactive intestinal peptide
VIP
66695

Vasopressin
ADH
66695

VDRL (Venereal Disease Research Laboratory)—microbial antibody testing
VDRL
69384

Viscosity of blood or plasma
VISC
65060

Vitamins—B12
B12
66599

Vitamins—D
VITD
66608

Vitamins—folate
RCF
66599

Vitamins—quantitation of A, B1, B2, B3, B6, C or E
VIT
66605

VMA (see HMMA)
 
 

Von Willebrand’s factor
VWF
65150

Von Willebrand’s factor antigen
VWA
65150

Warfarin
WFR
66812

Yersinia enterocolitica—microbial antibody testing
YER
69384

Zinc
ZN
66667–66670

Part 4—Complexity levels for histopathology items
  
 
Complexity levels for histopathology items

Specimen type
Complexity level

Adrenal resection, neoplasm
5

Adrenal resection, not neoplasm
4

Anus, all specimens not otherwise specified
3

Anus, neoplasm, biopsy
4

Anus, neoplasm, radical resection
6

Anus, submucosal resection—neoplasm
5

Appendix
3

Artery, all specimens not otherwise specified
3

Artery, biopsy
4

Bartholin’s gland—cyst
3

Bile duct, resection—all specimens
6

Bone—all specimens not otherwise specified
4

Bone, biopsy, curettings or fragments—lesion
5

Bone, biopsy or curettings quantitation—metabolic disease
6

Bone, femoral head
4

Bone marrow, biopsy
4

Bone, resection, neoplasm—all sites and types
6

Brain neoplasm, resection—cerebello‑pontine angle
4

Brain or meninges, biopsy—all lesions
5

Brain or meninges, not neoplasm—temporal lobe
6

Brain or meninges, resection—neoplasm (intracranial)
5

Brain or meninges, resection—not neoplasm
4

Branchial cleft, cyst
4

Breast, excision biopsy, guidewire localisation—non‑palpable lesion
6

Breast, excision biopsy, or radical resection, malignant neoplasm or atypical proliferative disease—all specimen types
6

Breast, incision biopsy or needle biopsy, malignant neoplasm—all specimen types
4

Breast, microdochectomy
6

Breast, orientated wide local excision for carcinoma with margin assessment
7

Breast tissue—all specimens not otherwise specified
4

Bronchus, biopsy
4

Carotid body—neoplasm
5

Cholesteatoma
3

Digits, amputation—not traumatic
4

Digits, amputation—traumatic
2

Ear, middle and inner—not cholesteatoma
4

Endocrine neoplasm—not otherwise specified
5

Extremity, amputation—not otherwise specified
4

Extremity, amputation or disarticulation—neoplasm
6

Eye, conjunctiva—biopsy or pterygium
3

Eye, cornea
4

Eye, enucleation or exenteration—all lesions
6

Eye—not otherwise specified
4

Fallopian tube, biopsy
4

Fallopian tube, ectopic pregnancy
4

Fallopian tube, sterilization
2

Fetus with dissection
6

Foreskin—new born
2

Foreskin—not new born
3

Gallbladder
3

Gallbladder and porta hepatis‑radical resection
6

Ganglion cyst, all sites
3

Gum or oral mucosa, biopsy
4

Heart—not otherwise specified
5

Heart valve
4

Hernia sac
2

Hydrocele sac
2

Jaw, upper or lower, including bone—radical resection for neoplasm
6

Joint and periarticular tissue, without bone—all specimens
3

Joint tissue, including bone—all specimens
4

Kidney, biopsy including transplant
5

Kidney, nephrectomy transplant
5

Kidney, partial or total nephrectomy—not neoplasm
4

Kidney, partial or total nephrectomy or nephroureterectomy—neoplasm
6

Large bowel, colostomy—stoma
3

Large bowel (including rectum), biopsy—all sites
4

Large bowel (including rectum), biopsy, for confirmation or exclusion of Hirschsprung’s Disease
5

Large bowel (including rectum), polyp
4

Large bowel (including rectum), segmental resection—neoplasm
6

Large bowel (including rectum), submucosal resection—neoplasm
5

Large bowel, segmental resection—colon, not neoplasm
5

Larynx, biopsy
4

Larynx, partial or total resection
5

Larynx, resection with nodes or pharynx or both
6

Lip biopsy—all specimens not mentioned
3

Lip wedge resection or local excision with orientation
4

Liver—all specimens not otherwise specified
5

Liver, hydatid cyst or resection for trauma
4

Liver, total or subtotal hepatectomy—neoplasm
6

Lung, needle or transbronchial biopsy
4

Lung, resection—neoplasm
6

Lung segment, lobar or total resection
6

Lung, wedge biopsy
5

Lymph node, biopsy—all sites
4

Lymph node, biopsy, for lymphoma or lymphoproliferative disorder
5

Lymph nodes, regional resection—all sites
5

Mediastinum mass
5

Muscle, biopsy
6

Nasopharynx or oropharynx, biopsy
4

Nerve, biopsy neuropathy
5

Nerve, neurectomy or removal of neoplasm
4

Nerve—not otherwise specified
3

Nose, mucosal biopsy
4

Nose or sinuses, polyps
3

Odontogenic neoplasm
5

Odontogenic or dental cyst
4

Oesophagus, biopsy
4

Oesophagus, diverticulum
3

Oesophagus, partial or total resection
6

Oesophagus, submucosal resection—neoplasm
5

Omentum, biopsy
4

Ovary with or without tube—neoplasm
5

Ovary with or without tube—not neoplasm
4

Pancreas, biopsy
5

Pancreas, cyst
4

Pancreas, subtotal or total with or without splenectomy
6

Parathyroid gland(s)
4

Penisectomy—simple
4

Penisectomy with node dissection
5

Peritoneum, biopsy
4

Pituitary neoplasm
4

Placenta—not third trimester
4

Placenta—third trimester, abnormal pregnancy or delivery
4

Pleura or pericardium, biopsy or tissue
4

Products of conception, spontaneous or missed abortion
4

Products of conception, termination of pregnancy
3

Prostate—all types of specimen not otherwise specified
4

Prostate, radical prostatectomy or cystoprostatectomy for carcinoma
7

Prostate, radical resection
6

Retroperitoneum, neoplasm
5

Salivary gland—all specimens not otherwise specified
4

Salivary gland, Mucocele
3

Salivary gland, neoplasm—all sites
5

Sinus, paranasal, biopsy
4

Sinus, paranasal, resection—neoplasm
6

Skin—all specimens not otherwise specified including all neoplasms and cysts
3

Skin, biopsy—blistering skin diseases
4

Skin, biopsy—inflammatory dermatosis
4

Skin, biopsy—investigation of alopecia where serial horizontal sections are taken, except for male pattern baldness
5

Skin, biopsy—investigation of lymphoproliferative disorder
5

Skin, eyelid, wedge resection
4

Skin, local resection—orientation
4

Skin, resection of malignant melanoma or melanoma in situ
5

Small bowel—all specimens not otherwise specified
5

Small bowel—biopsy, all sites
4

Small bowel, diverticulum
3

Small bowel, resection—neoplasm
6

Small bowel, submucosal resection—neoplasm
5

Soft tissue, infiltrative lesion—extensive resections at least 5 cm in maximal dimension
6

Soft tissue, lipoma and variants
3

Soft tissue, neoplasm, not lipoma—all specimens
5

Soft tissue—not otherwise specified
4

Spleen
5

Stomach—all specimens not otherwise specified
4

Stomach, endoscopic biopsy or endoscopic polypectomy
4

Stomach, resection, neoplasm—all specimens
6

Stomach, submucosal resection—neoplasm
5

Tendon or tendon sheath, giant cell neoplasm
4

Tendon or tendon sheath—not otherwise specified
3

Testis and adjacent structures, castration
2

Testis and adjacent structures, neoplasm with or without nodes
5

Testis and adjacent structures—not otherwise specified
3

Testis and adjacent structures, vas deferens sterilization
2

Testis, biopsy
5

Thymus—not otherwise specified
5

Thyroglossal duct—all lesions
4

Thyroid—all specimens
5

Tissue or organ—all specimens not otherwise specified
3

Tissue or organ not otherwise specified, abscess
3

Tissue or organ not otherwise specified, haematoma
3

Tissue or organ not otherwise specified, malignant neoplasm with regional nodes
6

Tissue or organ not otherwise specified, neoplasm local
4

Tissue or organ not otherwise specified, pilonidal cyst or sinus
3

Tissue or organ not otherwise specified, thrombus or embolus
3

Tissue or organ not otherwise specified, veins varicosity
3

Tongue, biopsy
4

Tongue or tonsil, neoplasm local
5

Tongue or tonsil, neoplasm with nodes
6

Tonsil, biopsy—excluding resection of whole organ
4

Tonsil or adenoids or both
2

Trachea, biopsy
4

Ureter, biopsy
4

Ureter, resection
5

Urethra, biopsy
4

Urethra, resection
5

Urinary bladder—all specimens not otherwise specified
4

Urinary bladder, partial or total with or without prostatectomy
6

Urinary bladder, transurethral resection of neoplasm
5

Uterus and/or cervix—all specimens not otherwise specified
4

Uterus, cervix cone, biopsy (including LEEP or LLETZ biopsy)
5

Uterus, cervix, curettings or biopsy
4

Uterus, endocervix, polyp
3

Uterus, endometrium, polyp
3

Uterus, with or without adnexa, malignant neoplasm—all specimen types not otherwise specified
6

Uterus with or without adnexa, neoplasm, Wertheim’s or pelvic clearance
6

Vagina, biopsy
4

Vaginal mucosa, incidental
3

Vagina, radical resection
6

Vulva or labia, biopsy
4

Vulval, subtotal or total with or without nodes
6

 
Part 5—Dictionary
Note:       All references in the Dictionary to a provision are references to a provision in this Schedule, unless otherwise indicated.
  
                   In this Schedule:
abnormal level of TSH, for item 66719, has the meaning given by clause 2.2.5.
Act means the Health Insurance Act 1973.
approved collection centre, for Group P10, has the meaning given by clause 2.10.1.
ASGC, for item 74991, has the meaning given by subclause 2.12.1(3).
biopsy material, for Group P5, has the meaning given by clause 2.5.1.
bulk‑billed, for items 74990 and 74991, has the meaning given by subclause 2.12.1(2).
Commonwealth concession card holder, for items 74990 and 74991, has the meaning given by subclause 2.12.1(2).
compatibility tests by crossmatch, for items 65099 and 65102, has the meaning given by clause 2.1.2.
cytology, for Group P5, has the meaning given by clause 2.5.1.
designated test, has the meaning given by clause 1.2.4.
elevated serum ferritin, for items 73317 and 73318, has the meaning given by clause 2.7.1.
general practitioner, has the meaning given by clause 1.2.6.
group, for a group in this table, means every item in the group.
Hepatitis C sero‑positive, for items 69499 and 69500, has the meaning given by clause 2.3.5.
institution, for Group P10, has the meaning given by clause 2.10.1.
item means:
                     (a)  an item mentioned, by number, in column 1 of a table in:
                              (i)  this Schedule; or
                             (ii)  the diagnostic imaging services table; or
                            (iii)  the general medical services table; or
                     (b)  in a reference immediately followed by a number—the item so numbered.
metal toxicity testing group, has the meaning given by clause 2.2.7.
nutritional metals testing group, has the meaning given by clause 2.2.7.
patient episode means:
                     (a)  a pathology service or pathology services (other than a pathology service to which paragraph (b) refers) provided for a single patient whose need for the service or services was determined under section 16A of the Act:
                              (i)  on the same day; or
                             (ii)  if more than one test is performed on the one specimen within 14 days—on the same or different days;
                            whether the services:
                            (iii)  are requested by one or more practitioners, participating midwives or participating nurse practitioners; or
                            (iv)  are described in a single item or in more than one item; or
                             (v)  are rendered by one approved pathology practitioner or more than one approved pathology practitioner; or
                            (vi)  are rendered on the same or different days; or
                     (b)  a pathology service to which clause 1.2.3, 2.1.1 or 2.2.2 refers that is provided in the circumstances, set out in the clause, that relate to the service.
practice location, for item 74991, has the meaning given by subclause 2.12.1(3).
prescribed laboratory, for Group P10, has the meaning given by clause 2.10.1.
receiving APP, for a patient episode, means an approved pathology practitioner in an approved pathology authority who:
                     (a)  receives a request from a referring APP to render a designated test or tests; and
                     (b)  renders each test included in the designated test that the referring APP has not performed.
recognised pathologist means:
                     (a)  a medical practitioner recognised as a specialist in pathology under subsection 3D(1) of the Act; or
                     (b)  a medical practitioner in relation to whom there is in force a determination under paragraph 3DB(4)(a) or subsection 3E(1) of the Act that the practitioner is recognised as a specialist in pathology.
referring APP, for a patient episode, means an approved pathology practitioner in an approved pathology authority who:
                     (a)  has received a request to render one or more designated tests; and
                     (b)  is unable, because of the lack of facilities in, or expertise or experience of the staff of, the laboratory of the authority, to render one or more of the tests included in the designated test; and
                     (c)  requests a receiving APP in another approved pathology authority to render:
                              (i)  the test or tests that the approved pathology practitioner is unable to render; or
                             (ii)  all of the tests that are included in the designated test; and
                     (d)  renders each test included in the designated test, other than the test or tests for which the request mentioned in paragraph (c) is made.
regional, rural or remote area, for item 74991, has the meaning given by subclause 2.12.1(3).
request, received by an approved pathology practitioner, includes a request for a pathologist‑determinable service to which subsection 16A(6) of the Act applies.
residential care facility, for Group P10, has the meaning given by clause 2.10.1.
rule 3 exemption means the exemption that has effect because of the operation of clause 1.2.2.
separately identified specimen, for Group P5, has the meaning given by clause 2.5.1.
serial examinations means a series of examinations requested on one occasion, whether or not:
                     (a)  the materials are received on different days by the approved pathology practitioner; or
                     (b)  the examinations or cultures were requested on one or more request forms by the treating practitioner.
serial examinations or cultures, for Group P3, has the meaning given by clause 2.3.1.
serological status is uncertain, for items 69499 and 69500, has the meaning given by clause 2.3.5.
set of pathology services, has the meaning given by clause 1.2.7.
SLA, for item 74991, has the meaning given by subclause 2.12.1(3).
specimen collection centre, for Group P10, has the meaning given by clause 2.10.1.
SSD for item 74991, has the meaning given by subclause 2.12.1(3).
treating practitioner, for Group P10, has the meaning given by clause 2.10.1.
unreferred service, for items 74990 and 74991, has the meaning given by subclause 2.12.1(3).
 
 
Schedule 2—Repeals
  
Health Insurance (Pathology Services Table) Regulation 2012
1  The whole of the regulation
Repeal the regulation.